

Exhibit 559

Group Life COVID-19 Mortality
Survey Report
SOA Research Institute

<https://www.soa.org/4ac0fd/globalassets/assets/files/resources/experience-studies/2023/group-life-covid-mort-06-23.pdf>



Group Life COVID-19 Mortality Survey Report



NOVEMBER | 2023



Group Life COVID-19 Mortality Survey Report

AUTHORS Patrick Hurley, FSA, MAAA
Mike Krohn, FSA, CERA, MAAA
Tony LaSala, FSA, MAAA
Rick Leavitt, ASA, MAAA
Cynthia S. MacDonald, FSA, MAAA, SOA
Patrick Nolan, FSA, MAAA, SOA
Steve Rulis, FSA, MAAA
Matthew Sawyer, FSA, MAAA

SPONSORS Group Life Experience Committee

 **Give us your feedback!**
Take a short survey on this report. [Click Here](#) 

Caveat and Disclaimer

The opinions expressed and conclusions reached by the authors are their own and do not represent any official position or opinion of the Society of Actuaries Research Institute, Society of Actuaries, or its members. The Society of Actuaries Research Institute makes no representation or warranty to the accuracy of the information.

Copyright © 2023 by the Society of Actuaries Research Institute. All rights reserved.

CONTENTS

Section 1: Purpose of the Survey	5
Section 2: Overview	6
2.1 Background	6
2.2 Scope	6
2.3 Survey Highlights	7
Section 3: Group Life Mortality Results—Reported Death Claims	11
3.1 Reported Claim Incidence by Count—All Causes.....	11
3.2 Reported Claim Incidence by Count—COVID-19 Versus All Other Causes.....	12
3.3 Reported Claim Incidence by Amount—All Causes	14
3.4 Reported Claim Incidence by Amount—COVID-19 Versus All Other Causes	14
Section 4: Group Life Mortality Results—Estimated Incurred Death Claims	15
4.1 Incurred Claim Incidence by Count—All Causes	15
4.2 Incurred Claim Incidence by Count—COVID-19 Versus All Other Causes	16
4.3 Incurred Claim Incidence by Amount—All Causes.....	18
4.4 Incurred Claim Incidence by Amount—COVID-19 Versus All Other Causes.....	18
4.5 Development of Face Amount Trend Assumption.....	18
4.6 Other Drivers of Amount Versus Count Mortality Differences	20
Section 5: Estimated Incurred Mortality Results by Segment	22
5.1 Industry	23
5.2 Geography.....	24
5.3 Age and Sex.....	25
5.4 Company Size.....	28
Section 6: Detailed Cause of Death	29
Section 7: Exposure Trends	36
7.1 Premiums	36
7.2 Lives	37
Section 8: Company Variations	39
8.1 Variations in COVID-19 Mortality Results.....	39
8.2 Variations in COVID-19 Claim Coding Procedures	40
8.3 Variations in Claim Reporting Patterns.....	40
Section 9: Comparisons to General U.S. Population Mortality Results	41
9.1 Aggregate Excess Mortality Comparisons	41
9.2 Excess Mortality Comparison by Age.....	42
9.3 Excess Mortality Comparison by Geographic Region	54
Section 11: List of Participating Companies	57
Appendix A: 2020 SOA Group Term Life COVID-19 Mortality Survey Data Request	58
Appendix B: Geography and Industry Code Mappings	61
Appendix C: Survey Methodology and Documentation	66
C.1 Documentation	66
C.2 Results Processing and Review	68
C.2.1 Completion of Claims.....	68
C.2.2 Broader Classification of Segment Information	68
C.2.3 Unknown Claim Diagnosis	68

C.2.4 COVID-19 Claims from 2019 or Earlier 69

C.2.5 Groupings by Company Size 69

Appendix D: Completion Factor Development 70

 D.1 By Claim Count 70

 D.2 By Face Amount..... 72

 D.3 By Cause of Death 72

 D.4 By Company Reporting Speed 73

Appendix E: Cause of Death Mapping 74

About The Society of Actuaries Research Institute 75

Group Life COVID-19 Mortality Survey Report

Section 1: Purpose of the Survey

The purpose of this survey was to gather a high-level view of U.S. Group Term Life Insurance mortality results during the COVID-19 pandemic, as compared to prior period baseline mortality results. COVID-19 is caused by the novel coronavirus SARS-CoV-2, which was identified in 2019. As of the writing of this document, complications from COVID-19 have resulted in more than 1.1 million deaths in the U.S. alone, and more than 6.9 million worldwide.

This report is an update to the previous [Group Life COVID-19 Mortality Survey](#) published in June 2023, which included pandemic data from April 2020 through December 2022. This update includes Group Life mortality results from April 2020 through June 2023 (referred to in this report as the “pandemic period”), representing 39 months of Group Life mortality experience during the COVID-19 pandemic.

The survey was conducted by the Group Life Experience Committee (the Committee) of the Society of Actuaries Research Institute and has been structured as a recurring monthly data collection and compilation process from U.S. Group Term Life insurers. The datasets for this report encompass all Group Term Life claims for the calendar years 2017–2022 and the first half of 2023 reported to participating carriers as of June 30, 2023, and include more than 2.9 million claims and more than \$131 billion in earned premium. The Committee is grateful that 20 of the top 21 U.S. Group Term Life insurers focused on employer groups participated in this survey, with market share representing roughly 90% of the employer-based Group Term Life industry. Thus, the Committee believes the findings herein are representative of the COVID-19 mortality impact on the U.S. Group Term Life industry as a whole.

Guiding principles for the survey include the following:

- Providing timely information on total high-level Group Life mortality results versus baseline expectations during the pandemic is the most important goal. Thus, the survey is *not* a seriatim mortality study. Rather, it is a synopsis of monthly Group Life exposures, death counts and amounts.
- It is critical for this survey to compare current Group Life mortality from all causes of death to the baseline expected all-cause mortality levels. The Committee recognizes the existence of limitations in the ability to code deaths as COVID-19 related, within both the general population and Group Life exposures. Also, the survey seeks to analyze whether the pandemic has had indirect impacts on population mortality, beyond deaths associated directly with the COVID-19 virus. Thus, tracking just Group Life deaths coded with a cause of COVID-19 may not accurately measure the total impact of the pandemic.
- The Committee asked carriers to provide segmentation data when feasible. However, the Committee did not want the additional detailed data request to become so onerous that it materially delayed the survey reporting process or shrank the number of carriers willing and able to participate. Thus, the survey included high-level exposure and claims data for all 20 carriers, but many of the segmentation data are based on results for just subsets of carriers.



Give us your feedback!

Take a short survey on this report.

[Click Here](#)

SOA
Research
INSTITUTE

Section 2: Overview

2.1 BACKGROUND

Carriers provided a complete set of monthly Group Life exposures dating back to January 2017, along with all Group Life death claims reported in January 2017 or later. The reported death claims also identified the months of death, that is, incurred months.

Exposures and deaths during the three-year period of 2017–2019 were used to set baseline mortality expectations. The dataset for this report encompasses all Group Life claims reported to participating carriers as of June 30, 2023. Reported claims are easier to measure than incurred claims, but they do not tell the full story about Group Life mortality through June 2023 because the reported claims in a given month include deaths from prior periods. Therefore, claim reporting patterns from prior periods have been analyzed to develop completion factors, which are used to estimate incurred, but not yet reported, claims for each month. This enabled the Committee to estimate incurred claims for each month up through June 2023.

As in prior reports, the most recent one-to-two incurral months should not be fully relied upon because of the maturity of the completion of reported claims, with the completion percentages for the most recent two months falling in the 30%–35% and 70%–75% ranges, respectively. The Committee has observed significant reporting lag volatility over the course of the study, resulting in volatility of incurred incidence development over time, especially in the most recent incurred months.

2.2 SCOPE

The following specifications were used to define claims and exposures within the survey:

- Include Group Term Life only; exclude Group Whole Life, Group Universal Life, Company-Owned Life Insurance and 10- or 20-year Group Term, etc.
- Include both list billed and self-administered business.
- Include employee, spouse and child exposures and deaths.
- Include both active and retired lives and claims.
- Include death benefits only; exclude riders, interest payments and claims expenses.
- Include only the life insurance benefit for accidental deaths; exclude any additional Accidental Death and Dismemberment rider amounts.
- Exclude Waiver of Premium disabilities, but include deaths from persons on Waiver of Premium status.
- Portability and Conversion exposures and claims may be either included or excluded based on each company's internal reporting procedures.

2.3 SURVEY HIGHLIGHTS

Tables 2.1 through 2.4¹ display high-level incidence results for the second quarter of 2020 through the second quarter of 2023 compared to the 2017–2019 baseline period for each combination of (a) incurred/reported basis and (b) count/amount basis as of June 30, 2023. In these tables, the number of COVID-19 claims has not been adjusted for seasonality, but the ratios to baseline have. Monthly face amounts have been trended at a 2% annual rate for low wage inflation years 2017-2019, and a 3% annual rate for high wage inflation years of 2020 and later. See section 4.5 of this report for further discussion on the trend assumptions.

Table 2.1

COUNT-BASED INCURRED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE

Count-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Total / Baseline	118.9%	121.5%	105.5%	96.8%	99.4%	98.1%	112.2%
COVID-19 Claims	46,644	78,494	27,620	2,376	700	3,076	155,834
COVID / Baseline	14.6%	18.4%	6.1%	2.0%	0.6%	1.3%	11.0%
Non-COVID / Baseline	104.3%	103.1%	99.4%	94.8%	98.8%	96.8%	101.2%

Table 2.2

AMOUNT-BASED INCURRED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE (CLAIMS IN MILLIONS)

Amount-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Total / Non-trended Baseline	125.2%	139.6%	118.9%	111.1%	116.0%	113.6%	125.7%
Total / Trended Baseline	119.4%	129.6%	107.3%	98.4%	102.0%	100.2%	115.7%
COVID-19 Claims (M)	1,721	3,998	1,124	68	24	93	6,935
COVID / Trended Baseline	14.1%	24.0%	6.2%	1.4%	0.5%	1.0%	12.5%
Non-COVID / Trended Baseline	105.3%	105.6%	101.1%	97.0%	101.5%	99.2%	103.2%

Table 2.3

COUNT-BASED REPORTED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE

Count-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Total / Baseline	115.3%	123.6%	108.9%	102.7%	95.3%	99.0%	113.2%
COVID-19 Claims	34,528	81,446	35,106	3,119	1,266	4,385	155,465
COVID / Baseline	11.2%	19.3%	7.8%	2.6%	1.1%	1.9%	11.1%
Non-COVID / Baseline	104.1%	104.3%	101.1%	100.1%	94.2%	97.1%	102.1%

Table 2.4

AMOUNT-BASED REPORTED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE (CLAIMS IN MILLIONS)

Amount-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Total / Non-trended Baseline	123.6%	140.6%	122.2%	116.8%	108.2%	112.5%	126.6%
Total / Trended Baseline	118.0%	130.8%	110.5%	103.7%	95.3%	99.5%	116.6%
COVID-19 Claims (M)	1,369	3,986	1,457	101	34	134	6,946
COVID / Trended Baseline	11.7%	24.4%	8.0%	2.1%	0.7%	1.4%	12.8%
Non-COVID / Trended Baseline	106.3%	106.4%	102.5%	101.6%	94.6%	98.1%	103.8%

¹ A small number of COVID-19 claims received were dated before 2020. The Committee assumes these dates are data errors. They were not assigned to a particular date in 2020 or later, and so these claims are excluded from Tables 2.1–2.4. They are, however, included in the total COVID claims in Section 5.

Reported incidence has decreased considerably since the first quarter of 2022. No months since March 2022 have had a reported incidence more than 10% above baseline. Of particular note, all three months in the second quarter of 2023 have been below baseline, with April, May, and June reported incidence at 7%, 2%, and 5% below baseline, respectively. All three months in the first quarter of 2023 were above baseline, but the maximum was in January at 5% above baseline.

It is important to note that incurred estimates for the most recent months lack credibility because of the low level of completion of the data used at the time of this analysis. Group Life claim completion has been especially volatile during the pandemic waves, driven both by the ultimate incurred levels fluctuating from month to month and company-specific claim-processing speeds fluctuating up and down because of increases or decreases in staffing levels and build-up or build-down of claim backlogs.

From an incurred mortality viewpoint, all of the months from April 2020 through December 2022 showed excess mortality² versus baseline expectations except for March and April 2022. However, in the first half of 2023, all months except June were below baseline on an incurred basis, with each month ranging from 5% below baseline to 1% above baseline. December 2020, January 2021, August 2021 and September 2021 all had very high incurred excess mortality spikes of 40% or more.

The 39-month period of April 2020 through June 2023 showed the following Group Life mortality results:

- Estimated reported Group Life claim incidence rates were up 13.2% on a seasonally-adjusted basis compared to 2017–2019 reported claims.
- Estimated incurred Group Life incidence rates were 12.2% higher than baseline on a seasonally-adjusted basis. As noted above, the incurred incidence rates in May and June 2023 are based on fairly incomplete data, so they are subject to change and should not be fully relied upon at this point.

Additional highlights include the following:

- Approximately 10% of all reported Group Life claims with death dates in the pandemic period were determined to have a cause of death (COD) of COVID-19.
- The Gray-Collar group had the lowest actual-to-expected ratios (A/E's) relative to baseline over the pandemic period at around 6%, followed by the Blue-Collar group at 10%. The White-Collar group continued to have the highest mortality A/E relative to baseline at 16% during the pandemic period.

²For the purposes of this report, “excess mortality” refers to the percentage change in incidence rates observed during the pandemic compared to the 2017–2019 baseline period.

- Group Life mortality patterns by region have changed over time during the COVID-19 pandemic. The Midwest had the highest excess mortality for the most recent quarter included in this update. The following regions had the highest excess mortality in each quarter shown:
 - Q1 2021: Southeast (32%)
 - Q2 2021: Southeast (10%)
 - Q3 2021: Southeast (62%)
 - Q4 2021: Midwest (32%)
 - Q1 2022: Northeast (19%)
 - Q2 2022: Northeast (2%)
 - Q3 2022: Southeast (7%)
 - Q4 2022: Northeast (8%)
 - Q1 2023: Northeast (1%)
 - Q2 2023: Midwest (6%)
- Findings related to COD data showed incurred mortality increases in several causes during the pandemic period, including accidents, liver, diabetes, and drug overdoses. Cardiovascular deaths were elevated in 2020 and 2021, but these fell below baseline in 2022. Cancer and influenza/pneumonia incurred mortality levels were down during the pandemic period as compared to baseline. Additional details are shown in Section 6.
- Early quarters of the pandemic period (Q2 and Q3 2020) showed the Group Life insured population studied within this survey experienced a lower percentage of excess deaths than the U.S. population, as shown in Table 2.5. Each quarter in 2021 showed higher excess mortality in the Group Life population than the U.S. population. However, in the second quarter of 2022, this comparison reversed, and Group Life population has shown lower excess mortality than the U.S. population in the most recent five quarters.

Table 2.5

GROUP LIFE AND U.S. POPULATION EXCESS MORTALITY PERCENTAGES BY QUARTER

Incurred Quarter	Group Life	U.S. Population	Difference
Q1 2020	-1.4%	0.1%	-1.5%
Q2 2020	14.4%	19.8%	-5.4%
Q3 2020	14.9%	16.7%	-1.8%
Q4 2020	28.0%	25.6%	2.4%
Q1 2021	22.4%	17.0%	5.4%
Q2 2021	6.5%	4.9%	1.6%
Q3 2021	32.8%	23.3%	9.6%
Q4 2021	24.6%	18.9%	5.7%
Q1 2022	16.6%	15.3%	1.2%
Q2 2022	-1.3%	1.8%	-3.1%
Q3 2022	2.9%	7.0%	-4.1%
Q4 2022	4.2%	7.4%	-3.2%
Q1 2023	-3.2%	-1.5%	-1.7%
Q2 2023	-0.6%	-0.4%	-0.2%

- Section 9 includes a comparison of proportional excess deaths in the Group Life market to the U.S. population, segmented by sex, age and cause of death. Overall, the experience between the two populations was quite similar but, in several instances, the experience differed:

- For the older ages (over age 65), Group Life mortality improved in 2022 and the first half of 2023 relative to 2020–2021 significantly more than in the U.S. population.
- Group Life mortality for major cardiovascular disease also improved in 2022 relative to 2020–2021 more than in the U.S. population.
- Mortality from cancer was significantly lower relative to 2017-2019 in the Group Life population than the U.S. population.
- The proportional impact of death due to liver disease was much higher within the total U.S. population than within the Group Life market through the entire pandemic period.


Section 3: Group Life Mortality Results—Reported Death Claims

3.1 REPORTED CLAIM INCIDENCE BY COUNT—ALL CAUSES

On a seasonally-adjusted basis, the second quarter of 2023 reported incidence by count was 95.3% of baseline levels, with April, May and June coming in at 93.0%, 97.9% and 95.2% of baseline, respectively. The second quarter of 2023 figure of 95.3% is far and away the lowest reported claim figure since the start of the pandemic.

Reported overall Group Life claim incidence rates during the pandemic period, as shown in Figure 3.1, were up approximately 13% compared to 2017–2019 reported claims. Reported claims are easier to measure than incurred because no estimation of completeness is required. However, reported claims do not explain the true economic impact of what is happening in the claim experience of a particular reported period, because those reported claims include deaths associated with prior periods, which may or may not have been accurately expected and accrued in prior period claim liabilities.

Figure 3.1
AGGREGATE REPORTED CLAIM INCIDENCE PER 1,000 BY CALENDAR YEAR AND MONTH³




³ Incidence rates in Figure 3.1 have not been adjusted for seasonality.

Figure 3.2 is a different view of the data displayed in Figure 3.1 to illustrate the flow of excess reported mortality over the entire pandemic period.

Figure 3.2

AGGREGATE REPORTED CLAIM INCIDENCE PER 1,000 BY CALENDAR MONTH⁴



3.2 REPORTED CLAIM INCIDENCE BY COUNT—COVID-19 VERSUS ALL OTHER CAUSES

A total of 155,465 COVID-19 death claims were reported during the pandemic period. Roughly 74% of the COVID-19 claims were for Basic Group Life coverage and roughly 26% for Supplemental/Voluntary coverage, with both figures including active employees and retirees. Note that the exposures and claim counts for insureds with both Basic and Supplemental/Voluntary coverage were included in both product lines. Thus, some deaths were counted as both Basic and Supplemental/Voluntary deaths, so the total number of Group Life insureds with COVID-19 deaths is less than 155,465.

Table 3.1 shows the total death claim incidence level (mortality rate) for each quarter during the pandemic relative to the baseline period metric. The table also shows a relativity for COVID-19 claims and non-COVID claims. As the table illustrates, COVID-19 claims do not fully explain the increase in reported claim incidence over the baseline period.

Table 3.1

COUNT-BASED REPORTED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE

Count-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Total / Baseline	115.3%	123.6%	108.9%	102.7%	95.3%	99.0%	113.2%
COVID-19 Claims	34,528	81,446	35,106	3,119	1,266	4,385	155,465
<i>COVID / Baseline</i>	11.2%	19.3%	7.8%	2.6%	1.1%	1.9%	11.1%
<i>Non-COVID / Baseline</i>	104.1%	104.3%	101.1%	100.1%	94.2%	97.1%	102.1%

⁴ Incidence rates in Figure 3.2 have not been adjusted for seasonality.

Reported claim details by month are shown in Table 3.2, along with calculated monthly reported incidence rates. Note that a small number of COVID-19 claims have reported dates of death in 2019 or prior, which are likely due to data errors.

Table 3.2
REPORTED CLAIMS AND INCIDENCE RATES, 2017 THROUGH Q2 2023

Report Date	Raw Submitted Numbers			Calculated Amounts				
	Reported Claims		Premium (\$ 000)	Life Years Exposed (000)		Annual Incidence per 1,000 (Lives Basis)	Adjusted for Seasonality	
	Total	COVID		By Month	Yearly Avg		Total	Total/Baseline
6/1/23	33,951	267	1,871,102	11,241	11,356	2.99	3.08	95.2%
5/1/23	37,860	434	1,877,852	11,209	11,356	3.33	3.17	97.9%
4/1/23	35,058	565	1,911,386	11,419	11,356	3.09	3.01	93.0%
3/1/23	42,030	900	1,921,002	11,425	11,356	3.70	3.31	102.2%
2/1/23	37,786	975	1,883,563	11,211	11,356	3.33	3.27	100.9%
1/1/23	42,163	1,244	1,934,365	11,631	11,356	3.71	3.40	105.2%
12/1/22	36,945	943	1,824,668	11,292	11,217	3.29	3.55	109.7%
11/1/22	35,834	919	1,808,505	11,170	11,217	3.19	3.53	109.0%
10/1/22	34,832	956	1,815,888	11,222	11,217	3.11	3.12	96.4%
9/1/22	36,013	1,156	1,817,245	11,215	11,217	3.21	3.55	109.5%
8/1/22	39,430	1,343	1,807,194	11,200	11,217	3.52	3.41	105.5%
7/1/22	35,966	1,211	1,816,599	11,300	11,217	3.21	3.35	103.5%
6/1/22	37,708	1,266	1,812,229	11,237	11,217	3.36	3.46	107.0%
5/1/22	37,169	1,568	1,815,153	11,202	11,217	3.31	3.15	97.3%
4/1/22	37,800	2,412	1,817,729	11,254	11,217	3.37	3.29	101.5%
3/1/22	49,506	6,139	1,808,172	11,120	11,217	4.41	3.94	121.8%
2/1/22	46,274	8,493	1,807,139	11,235	11,217	4.13	4.05	125.1%
1/1/22	47,772	8,700	1,803,927	11,158	11,217	4.26	3.91	120.6%
12/1/21	44,423	7,042	1,765,067	11,203	10,873	4.09	4.41	136.1%
11/1/21	41,590	7,085	1,707,329	10,837	10,873	3.83	4.22	130.5%
10/1/21	44,182	9,573	1,720,116	10,824	10,873	4.06	4.08	126.2%
9/1/21	47,171	10,175	1,709,594	10,746	10,873	4.34	4.79	148.0%
8/1/21	41,654	4,878	1,703,536	10,812	10,873	3.83	3.72	115.0%
7/1/21	36,466	1,849	1,723,203	10,790	10,873	3.35	3.50	108.3%
6/1/21	40,029	2,760	1,727,820	10,874	10,873	3.68	3.79	117.2%
5/1/21	36,708	3,531	1,736,904	10,907	10,873	3.38	3.21	99.2%
4/1/21	41,619	4,950	1,740,571	10,916	10,873	3.83	3.73	115.3%
3/1/21	50,692	8,209	1,729,881	10,874	10,873	4.66	4.17	128.7%
2/1/21	47,489	10,360	1,722,093	10,867	10,873	4.37	4.29	132.4%
1/1/21	48,348	11,034	1,716,491	10,829	10,873	4.45	4.08	126.0%
12/1/20	46,526	8,065	1,687,891	10,960	10,993	4.23	4.58	141.4%
11/1/20	36,656	3,689	1,666,831	10,869	10,993	3.33	3.69	114.1%
10/1/20	38,686	2,814	1,668,634	10,775	10,993	3.52	3.55	109.6%
9/1/20	38,681	3,167	1,671,782	10,849	10,993	3.52	3.90	120.4%
8/1/20	38,240	3,452	1,674,383	10,894	10,993	3.48	3.39	104.7%
7/1/20	39,627	2,944	1,694,220	10,982	10,993	3.60	3.78	116.7%
6/1/20	39,526	3,184	1,683,613	10,946	10,993	3.60	3.71	114.8%
5/1/20	38,655	4,033	1,739,128	11,469	10,993	3.52	3.35	103.6%
4/1/20	40,846	3,180	1,695,716	10,889	10,993	3.72	3.63	112.2%
3/1/20	37,818	157	1,699,598	10,978	10,993	3.44	3.08	95.2%
2/1/20	36,414	3	1,726,512	11,297	10,993	3.31	3.15	97.2%
1/1/20	39,359	4	1,688,956	11,009	10,993	3.58	3.29	101.7%
2017-2019 Baseline	34,659	1	1,592,757	10,713	10,713	3.24	3.24	100.0%
2019 Monthly	35,494	1	1,647,480	10,884	10,884	3.26	3.27	100.9%
2018 Monthly	34,738	1	1,589,156	10,685	10,685	3.25	3.25	100.4%
2017 Monthly	33,744	0	1,541,634	10,572	10,572	3.19	3.20	98.7%

3.3 REPORTED CLAIM INCIDENCE BY AMOUNT—ALL CAUSES

Reported overall Group Life claim incidence rates by amount during the pandemic period were up 26.6% compared to 2017–2019 raw reported amounts, as shown in the first row of Table 3.3. The second row of Table 3.3 shows the pandemic period mortality increase by amount drops to 16.6% when incorporating a face amount trend assumption, which recognizes anticipated face amount growth as salaries and associated Group Life coverage amounts increase over time. Monthly face amounts have been trended at a 2% annual rate for low wage inflation years 2017-2019, and a 3% annual rate for high wage inflation years of 2020 and later. The A/E ratio by trended amount is approximately 3%-4% higher than the A/E ratio by count. Supporting details and further discussion of the trend amount assumptions are documented in Section 4.5 of this report.

3.4 REPORTED CLAIM INCIDENCE BY AMOUNT—COVID-19 VERSUS ALL OTHER CAUSES

Table 3.3

AMOUNT-BASED REPORTED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE (CLAIMS IN MILLIONS)


Amount-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
<i>Total / Non-trended Baseline</i>	123.6%	140.6%	122.2%	116.8%	108.2%	112.5%	126.6%
<i>Total / Trended Baseline</i>	118.0%	130.8%	110.5%	103.7%	95.3%	99.5%	116.6%
<i>COVID-19 Claims (M)</i>	1,369	3,986	1,457	101	34	134	6,946
<i>COVID / Trended Baseline</i>	11.7%	24.4%	8.0%	2.1%	0.7%	1.4%	12.8%
<i>Non-COVID / Trended Baseline</i>	106.3%	106.4%	102.5%	101.6%	94.6%	98.1%	103.8%

Section 4: Group Life Mortality Results—Estimated Incurred Death Claims

4.1 INCURRED CLAIM INCIDENCE BY COUNT—ALL CAUSES

A completed estimate of incurred incidence rates by count indicates that excess mortality for the pandemic period was approximately 12% higher than the 2017–2019 baseline incurred incidence. Figure 4.1 displays the various monthly estimated incurred incidence rates.

Figure 4.1
AGGREGATE INCURRED⁵ CLAIM INCIDENCE PER 1,000 BY CALENDAR YEAR AND MONTH




Current estimates for the second quarter of 2023 incurred incidence rates indicate that mortality was 99.4% of baseline on a seasonally-adjusted count basis. The monthly results within the second quarter of 2023 show April and May estimated incurred mortality slightly below baseline at 97.3% and 99.9%, respectively, while June is above baseline at 101.0%. The May and June results are still highly incomplete and likely to change as more months of reported claims are revealed.

The current view of the first quarter of 2023 results indicates incurred mortality was 96.8% of baseline, with each of the three months of the quarter coming in below baseline.

⁵ Adjusted for assumed completion.

Figure 4.2 is a different view of the data displayed in Figure 4.1 to illustrate the flow of estimated excess incurred mortality over the entire pandemic period.

Figure 4.2
AGGREGATE INCURRED⁶ CLAIM INCIDENCE PER 1,000 BY CALENDAR MONTH⁷



4.2 INCURRED CLAIM INCIDENCE BY COUNT—COVID-19 VERSUS ALL OTHER CAUSES

Similar to reported claim metrics, Table 4.1 shows that COVID-19 claims do not fully explain the increase in incurred claim incidence on a count basis. COVID-19 claims account for roughly 90% of the excess incurred Group Life mortality during the second quarter of 2020 through the second quarter of 2023, with the other 10% coming from claims that were not coded with COVID-19 as the cause of death.

Table 4.1
INCURRED EXCESS MORTALITY BY CLAIM COUNT COMPARED TO 2017–2019 BASELINE

Count-Based	Q2 2020–Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020–Q2 2023
Total / Baseline	118.9%	121.5%	105.5%	96.8%	99.4%	98.1%	112.2%
COVID-19 Claims	46,644	78,494	27,620	2,376	700	3,076	155,834
COVID / Baseline	14.6%	18.4%	6.1%	2.0%	0.6%	1.3%	11.0%
Non-COVID / Baseline	104.3%	103.1%	99.4%	94.8%	98.8%	96.8%	101.2%

⁶ Adjusted for assumed completion.

⁷ Incidence rates in Figure 4.2 have not been adjusted for seasonality.

Incurred claim details by month are shown in Table 4.2, along with calculated monthly incurred incidence rates. Note that a small number of COVID-19 claims have incurred dates of death in 2019 or prior, which are likely due to data errors.

Table 4.2
INCURRED CLAIM COUNTS AND INCIDENCE RATES, 2017 THROUGH Q2 2023

Incurrence Date	Raw Submitted Numbers				Calculated Amounts			
	Average Incurred Claim Counts		Average Premium (\$ 000)	Average Life Years Exposed (000)	Average Completed Claim Counts	Annual Incidence per 1,000 (Lives Basis)	Adjusted for Seasonality	
	Total	COVID					Total	Total/Baseline
6/1/23	11,609	42	1,871,102	11,241	35,047	3.12	3.28	101.0%
5/1/23	25,727	145	1,877,852	11,209	35,989	3.21	3.24	99.9%
4/1/23	30,159	309	1,911,386	11,419	35,549	3.11	3.16	97.3%
3/1/23	33,730	514	1,921,002	11,425	37,300	3.26	3.08	95.0%
2/1/23	32,296	615	1,883,563	11,211	34,689	3.09	3.15	97.1%
1/1/23	38,660	1,095	1,934,365	11,631	40,934	3.52	3.19	98.3%
12/1/22	39,642	1,140	1,824,668	11,292	41,346	3.66	3.45	106.4%
11/1/22	36,090	747	1,808,505	11,170	37,399	3.35	3.40	104.8%
10/1/22	35,835	770	1,815,888	11,222	36,961	3.29	3.29	101.3%
9/1/22	34,432	869	1,817,245	11,215	35,385	3.16	3.36	103.5%
8/1/22	35,165	1,203	1,807,194	11,200	36,035	3.22	3.33	102.6%
7/1/22	35,897	1,139	1,816,599	11,300	36,691	3.25	3.33	102.6%
6/1/22	34,122	878	1,812,229	11,237	34,793	3.10	3.26	100.3%
5/1/22	35,413	712	1,815,153	11,202	36,039	3.22	3.25	100.2%
4/1/22	33,856	590	1,817,729	11,254	34,404	3.06	3.10	95.6%
3/1/22	37,198	1,652	1,808,172	11,120	37,747	3.39	3.21	98.8%
2/1/22	40,425	5,999	1,807,139	11,235	40,976	3.65	3.71	114.4%
1/1/22	53,489	11,452	1,803,927	11,158	54,162	4.85	4.40	135.6%
12/1/21	46,808	8,054	1,765,067	11,203	47,349	4.23	3.99	122.8%
11/1/21	42,234	5,730	1,707,329	10,837	42,686	3.94	4.00	123.3%
10/1/21	44,531	7,914	1,720,116	10,824	44,968	4.15	4.15	127.8%
9/1/21	48,639	12,680	1,709,594	10,746	49,077	4.57	4.86	149.8%
8/1/21	47,153	10,048	1,703,536	10,812	47,543	4.40	4.55	140.2%
7/1/21	37,009	1,959	1,723,203	10,790	37,290	3.46	3.54	109.2%
6/1/21	34,992	1,354	1,727,820	10,874	35,233	3.24	3.41	105.0%
5/1/21	37,348	2,470	1,736,904	10,907	37,581	3.45	3.48	107.3%
4/1/21	37,225	3,053	1,740,571	10,916	37,435	3.43	3.48	107.2%
3/1/21	39,435	3,334	1,729,881	10,874	39,638	3.65	3.44	106.1%
2/1/21	41,148	6,779	1,722,093	10,867	41,338	3.80	3.87	119.3%
1/1/21	54,444	14,523	1,716,491	10,829	54,672	5.05	4.58	141.0%
12/1/20	53,447	13,359	1,687,891	10,960	53,650	4.90	4.63	142.7%
11/1/20	43,876	7,197	1,666,831	10,869	44,021	4.05	4.13	127.1%
10/1/20	39,404	3,107	1,668,634	10,775	39,520	3.67	3.67	113.1%
9/1/20	36,613	2,395	1,671,782	10,849	36,705	3.38	3.61	111.3%
8/1/20	39,851	3,707	1,674,383	10,894	39,938	3.67	3.80	117.2%
7/1/20	40,163	3,748	1,694,220	10,982	40,185	3.66	3.76	115.9%
6/1/20	36,118	1,971	1,683,613	10,946	36,138	3.30	3.48	107.3%
5/1/20	39,475	3,891	1,739,128	11,469	39,497	3.44	3.49	107.5%
4/1/20	44,691	7,162	1,695,716	10,889	44,716	4.11	4.18	128.8%
3/1/20	38,675	1,086	1,699,598	10,978	38,696	3.52	3.34	102.8%
2/1/20	35,356	23	1,726,512	11,297	35,376	3.13	3.09	95.1%
1/1/20	38,484	63	1,688,956	11,009	38,505	3.50	3.18	98.0%
2017-2019 Baseline	34,757	2	1,592,757	10,713	34,776	3.25	3.25	100.0%
2019 Monthly	34,905	3	1,647,480	10,884	34,924	3.21	3.21	98.9%
2018 Monthly	34,795	2	1,589,156	10,685	34,814	3.26	3.26	100.3%
2017 Monthly	34,572	1	1,541,634	10,572	34,591	3.27	3.27	100.8%

4.3 INCURRED CLAIM INCIDENCE BY AMOUNT—ALL CAUSES

Overall, seasonally-adjusted incurred Group Life claim incidence rates by amount during the pandemic period were up 25.7% compared to 2017–2019 raw incurred amounts, as shown in row 1 of Table 4.3. Row 2 of Table 4.3 shows the pandemic period mortality increase by amount drops to 15.7% when incorporating a face amount trend assumption, which recognizes anticipated face amount growth as salaries and associated Group Life coverage amounts increase over time. Monthly face amounts have been trended at a 2% annual rate for low wage inflation years 2017-2019, and a 3% annual rate for high wage inflation years of 2020 and later.

The increase in incidence rates by raw amount has been materially greater than the corresponding increase in incidence rates by count, with the raw amount impact consistently being 12%-15% higher on an additive basis. Prior iterations of this report suggested the difference was likely driven by salary and face amount inflation over the five-year period, along with changes in age and gender mix and the relatively higher excess mortality being incurred at typical working ages (where face amounts are greater).

The new trend component suggests most, but not all, of the difference between amount and count mortality impact can, indeed, be explained by salary increases and corresponding face amount increases over time. Incurred mortality by trended amount during 2023 is roughly 2%-3% higher than incurred mortality by count. Incurred mortality by trended amount peaked at roughly 15% greater than incurred mortality by count in the third quarter of 2021, and the additional mortality for trended amount versus count for the entire pandemic period is 3.5% on an additive basis (15.7% by trended amount versus 12.2% by count).

4.4 INCURRED CLAIM INCIDENCE BY AMOUNT—COVID-19 VERSUS ALL OTHER CAUSES

Table 4.3 displays both raw amount- and trended amount-based incurred incidence results versus baseline. The trended amount results are further split into COVID-19 and non-COVID impacts. Similar to the findings on incidence by count, Table 4.3 shows that COVID-19 claims do not fully explain the increase in incurred claim incidence on a trended amount basis.

Table 4.3

AMOUNT-BASED INCURRED INCIDENCE RESULTS RELATIVE TO 2017–2019 BASELINE

Amount-Based	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
<i>Total / Non-trended Baseline</i>	125.2%	139.6%	118.9%	111.1%	116.0%	113.6%	125.7%
<i>Total / Trended Baseline</i>	119.4%	129.6%	107.3%	98.4%	102.0%	100.2%	115.7%
<i>COVID-19 Claims (M)</i>	1,721	3,998	1,124	68	24	93	6,935
<i>COVID / Trended Baseline</i>	14.1%	24.0%	6.2%	1.4%	0.5%	1.0%	12.5%
<i>Non-COVID / Trended Baseline</i>	105.3%	105.6%	101.1%	97.0%	101.5%	99.2%	103.2%

4.5 DEVELOPMENT OF FACE AMOUNT TREND ASSUMPTION

The Committee has observed that premium per life has been increasing throughout the experience period, indicating average face amount insured has likely been increasing as well. The decision was made to build in an expected trended amount adjustment by calendar year to enhance the amount-based A/E metric. Wage data from the Federal Reserve is summarized in Table 4.4, with the rightmost column displaying the median nominal wage data, which is the sum of the real median wage change plus the CPI change. Based on this data, the Committee decided to trend expected amounts by 2% for years 2017-2019 and 3% for years 2020-2023. Trended claim amounts were increased prior to January 2020, and reduced for January 2020 forward, with January 1, 2020 being used as the pivot point for this calculation. The impact of adding this trend adjustment to the amount-based A/E was an average reduction by incurred calendar year as follows: 6% for quarters two through four of 2020, 10% for

2021, 12% for 2022, and 13% for quarters one and two of 2023. With this trended amount adjustment, the experience now reflects that the most meaningful impact of increased average severity occurred in 2021, but has been relatively muted otherwise.

These annual amount adjustment values are dampened from the raw wage data, as we acknowledge certain Group Life plans offer flat dollar benefits that do not increase annually. The same adjustment is applied by reported year and incurred year for simplicity. The assumption for future experience years will be monitored as wage data emerges. The Committee did consider differentiating this adjustment by age band and/or retirees as older ages often have flat benefit amounts, but the data and workbook limitations precluded this from being a viable possibility.

Table 4.4
U.S. WAGE DATA

Year	Average Hourly Earnings Change ⁸	Median Real Weekly Wage Change ⁹	CPI Change ¹⁰	Median Nominal Wage Change
2017	2.7%	-1.1%	2.1%	1.0%
2018	3.6%	2.9%	2.4%	5.3%
2019	2.9%	2.0%	1.8%	3.8%
2020	5.5%	4.1%	1.2%	5.3%
2021	5.0%	-4.0%	4.7%	0.7%
2022	4.8%	0.3%	8.0%	8.3%

⁸ <https://fred.stlouisfed.org/series/CES0500000003>


⁹ <https://fred.stlouisfed.org/series/LES1252881600Q>

¹⁰ <https://www.minneapolisfed.org/about-us/monetary-policy/inflation-calculator/consumer-price-index-1913->

4.6 OTHER DRIVERS OF AMOUNT VERSUS COUNT MORTALITY DIFFERENCES

Figure 4.3 below shows a stacked bar graph of incurred excess mortality, broken out by the count- and trended amount-based impacts. In addition, the percentage of U.S. population COVID-19 deaths occurring under age 65 are layered on top of this graph. The strong correlation between the amount-based excess and the under age 65 COVID-19 deaths may provide support for the hypothesis that a younger average death age of Group Life claims is a key component in driving higher amount-based excess mortality.

Figure 4.3
GROUP LIFE EXCESS INCURRED MORTALITY – COUNT AND TRENDED AMOUNT IMPACTS



The Committee also attempted to quantify the impact of changes in age and sex distribution over time, as displayed in Table 4.5. For each calendar year, the figures below show what the total average trended benefit would have been had we matched the 2022 average amounts by sex and age, but used the baseline distribution by sex and age. For 2022 as an example, the average trended amount would have been 36,514 rather than 37,731, so the impact of the distribution alone was 3.3%. This suggests that, if the distribution for age and sex matched the baseline period, the trended amount-based A/E would have been 3.3% lower than what we observed. The analysis also suggests that the big jump in 2021 mortality by trended amounts versus count was due to more than the ages of the deaths.

Table 4.5

ESTIMATE OF IMPACT OF CHANGE IN AGE AND SEX DISTRIBUTION OVER TIME ON AMOUNT-BASED A/E

Year ¹¹	2020	2021	2022	2023
(A) Trended amount-based A/E minus count-based A/E	0.3%	6.5%	1.3%	2.1%
(B) Actual average trended amount	37,367	39,671	37,731	37,969
(C) Trended amount using baseline sex/age distribution	36,647	36,654	36,514	35,840
(D) Impact of baseline distribution on trended amount-based A/E	2.0%	8.2%	3.3%	5.9%
(E) Residual difference between trended amount-based A/E and count-based A/E [(A) minus (D)]	-1.7%	-1.6%	-2.0%	-3.8%

¹¹ 2020 through 2022 represent full calendar years, including months in 2020 prior to the pandemic period. 2023 includes January through June 2023.

Section 5: Estimated Incurred Mortality Results by Segment

Analysis of results by segment will focus on claim count experience for simplicity and credibility. Results by claim amount generally follow similar patterns as the results by claim count.

The following notes apply to the data presented in this section:

- Claims and A/E ratios are presented on an incurred basis. The “expected” basis is the 2017–2019 baseline.
- Although most companies were able to provide segment detail, some did not. Results by Company Size reflect all companies. Results for Industry reflect approximately 97% of total company claims, results for Geography reflect 98% of total company claims, and results by Age reflect approximately 91% of total company claims. Note that these percentages are expressed relative to baseline claim counts.
- The total claim counts and A/E ratios in each subsection include only the data from companies that produced the breakout being analyzed. For example, the “All Industries” row in Table 5.2 includes only data from companies that were able to supply claims data by Industry. This can result in differences in the total A/E ratios across the various tables.
- The “% COVID” columns in the tables below show the monthly average COVID claims during the pandemic period as a percentage of the average total monthly claims from the 2017–2019 baseline period. The “% Non-COVID” column in the Age tables reflects excess mortality due to non-COVID claims.
- The “% Count” columns in the tables below show the proportion of baseline claims in each segment. For some segments, claims were submitted with an “Unknown” segmentation value. The unknowns and their ratios are usually omitted from the tables, but are included in the totals. Unknowns tend to account for a small percent of the total.

For formatting purposes, the quarterly information for older periods may be either aggregated or dropped from some tables in this section; see prior iterations of this report for information on quarterly excess mortality for these older periods.

5.1 INDUSTRY

Table 5.1 displays quarterly A/E mortality ratios by industry collar. The White-Collar category has experienced a higher A/E ratio than the Blue- and Grey-Collar industries over the entire pandemic period, and this relationship has been relatively consistent across time. All three categories showed peak excess mortality in the third quarter of 2021. Grey-Collar has had the lowest A/E ratio since the fourth quarter of 2021, including ratios below 100% for five consecutive quarters.

Table 5.1

EXCESS MORTALITY BY INDUSTRY COLLAR

Industry Collar	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	1Q 2023	2Q 2023	4/20-6/23	% COVID	% Count
Blue	123%	106%	129%	125%	115%	97%	101%	102%	94%	96%	110%	11.7%	40%
Grey	118%	104%	133%	121%	107%	89%	93%	90%	84%	86%	106%	11.9%	19%
White	123%	107%	138%	125%	120%	104%	108%	112%	102%	105%	116%	11.1%	40%
All Collars¹²	122%	107%	133%	125%	116%	99%	103%	104%	97%	100%	113%	11.5%	100%

Tables 5.2 and 5.3 show more detailed industry results for the top 10 industry segments by number of COVID claims. These are the same top 10 industry groupings and in the same order from the prior public report. Public Administration (White-Collar), Manufacturing–Auto, Airplanes (Blue-Collar), Misc. Services (Grey-Collar) and Educational Services (White-Collar) have had the highest A/E ratios since April 2020. Manufacturing–Heavy, Steel (Blue-Collar) had the lowest A/E ratio of the top 10 industries. In these tables, “B,” “W,” and “G” refer to Blue-Collar, White-Collar, and Grey-Collar, respectively.

Table 5.2

EXCESS MORTALITY FOR TOP 10 INDUSTRIES BY NUMBER OF COVID CLAIMS

Industry	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	1Q 2023	2Q 2023	4/20-6/23
W-Public Administration	122%	107%	146%	135%	133%	113%	110%	119%	111%	114%	122%
B-Transport; Communication; Utilities	119%	102%	129%	121%	113%	97%	100%	100%	93%	95%	109%
B-Manufacturing - Auto, Airplanes	130%	118%	131%	140%	129%	108%	112%	117%	108%	122%	120%
B-Manufacturing - Heavy; Steel	111%	96%	113%	115%	100%	85%	88%	90%	81%	75%	99%
W-Educational Services	122%	106%	135%	116%	106%	97%	116%	113%	102%	112%	114%
W-Doctors’ Offices	118%	103%	131%	113%	109%	95%	100%	100%	90%	95%	109%
G-Manufacturing - Paper; Drugs	124%	106%	127%	122%	109%	85%	89%	88%	81%	76%	104%
G-Retail - Trade	118%	101%	137%	121%	104%	82%	92%	89%	84%	84%	102%
G-Wholesale Trade	103%	96%	120%	115%	97%	86%	87%	84%	78%	90%	103%
G-Misc Service/Data Processing	126%	113%	152%	125%	120%	106%	109%	103%	95%	97%	116%
All Industries¹³	122%	107%	133%	125%	116%	99%	103%	104%	97%	100%	113%

¹² Includes only companies that provided industry splits; see second bullet at the beginning of Section 5.

¹³ Includes only companies that provided industry splits; see second bullet at the beginning of Section 5.

Table 5.3
COVID CLAIMS FOR TOP 10 INDUSTRIES BY NUMBER OF COVID CLAIMS

Industry	4/20-6/23	% COVID	% Count	# COVID
W-Public Administration	122%	10.8%	14%	20,677
B-Transport; Communication; Utilities	109%	11.7%	13%	20,405
B-Manufacturing - Auto, Airplanes	120%	12.0%	9%	14,460
B-Manufacturing - Heavy; Steel	99%	10.6%	9%	12,328
W-Educational Services	114%	10.9%	6%	9,378
W-Doctors' Offices	109%	11.8%	6%	8,998
G-Manufacturing - Paper; Drugs	104%	10.5%	6%	8,291
G-Retail - Trade	102%	12.7%	4%	7,371
G-Wholesale Trade	103%	11.4%	5%	7,013
G-Misc Service/Data Processing	116%	13.4%	3%	5,775
All Industries¹⁴	113%	11.5%	100%	153,436

It should be noted that the high A/E ratios for Public Administration are driven by experience in the Executive, Legislative and General Government segment (Standard Industry Classification [SIC] codes 9100–9199). This segment does not include police and fire and consistently represents more than 80% of claims in the broader Public Administration segment.

5.2 GEOGRAPHY

Results by Geography appear to be consistent with broad population results in terms of timing of regional spikes across the country, as shown in Table 5.4. The Southeast shows the highest overall A/E ratio since April 2020, as well as the highest percentage of claims identified as COVID. Smaller differences were seen in A/E ratio by region starting in early 2022, but more material differences can be seen in recent quarters, with the West region being favorable and the Midwest being the most unfavorable in the second quarter of 2023.

Table 5.4
EXCESS MORTALITY BY GEOGRAPHIC REGION

Region	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20-6/23	% COVID	% Count
Northeast	123%	108%	116%	122%	119%	102%	100%	108%	101%	100%	113%	9.7%	21%
West	130%	105%	132%	127%	114%	101%	104%	104%	96%	86%	112%	11.3%	15%
Midwest	108%	105%	117%	132%	117%	97%	102%	103%	94%	106%	110%	10.9%	28%
Southeast	132%	110%	162%	123%	118%	99%	107%	106%	99%	104%	117%	13.6%	35%
All Regions¹⁵	122%	107%	134%	125%	116%	99%	103%	105%	97%	100%	113%	11.5%	100%

¹⁴ Includes only companies that provided Industry splits; see second bullet at the beginning of Section 5.

¹⁵ Includes only companies that provided Geography splits; see second bullet at the beginning of Section 5.

A closer look at the states with the highest number of COVID claims in Tables 5.5 and 5.6 shows results that are consistent with the regional results in Table 5.4. Three Southeast states (Georgia, Tennessee, and Florida) contributed to the high cumulative A/E for the Southeast. The high A/E ratios in Michigan and Illinois contributed to the deterioration in Midwest results in the second quarter of 2023. Similarly, the low A/E ratio for California is in line with the favorable West result for the quarter.

Table 5.5**EXCESS MORTALITY FOR TOP 10 STATES BY NUMBER OF COVID CLAIMS**

State	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20-6/23
TX - Southeast	137%	104%	159%	117%	114%	97%	104%	100%	96%	102%	115%
CA - West	149%	103%	129%	114%	116%	100%	103%	102%	97%	80%	112%
FL - Southeast	127%	116%	185%	118%	114%	101%	109%	104%	102%	102%	118%
MI - Midwest	109%	116%	110%	144%	115%	99%	104%	102%	97%	114%	113%
OH - Midwest	111%	100%	115%	136%	114%	89%	95%	97%	88%	97%	106%
GA - Southeast	146%	117%	178%	133%	121%	104%	114%	109%	107%	115%	125%
PA - Northeast	121%	108%	114%	132%	116%	99%	97%	107%	98%	99%	111%
IL - Midwest	108%	102%	112%	118%	115%	94%	98%	101%	91%	107%	108%
NY - Northeast	131%	109%	112%	116%	116%	101%	96%	107%	97%	96%	113%
TN - Southeast	130%	116%	159%	136%	126%	100%	112%	115%	99%	105%	120%
All States¹⁶	122%	107%	134%	125%	116%	99%	103%	105%	97%	100%	113%

Table 5.6**COVID CLAIMS FOR TOP 10 STATES BY NUMBER OF COVID CLAIMS**

State	4/20-6/23	% COVID	% Count	# COVID
TX - Southeast	115%	16.1%	8%	17,794
CA - West	112%	11.7%	6%	10,026
FL - Southeast	118%	11.3%	6%	9,376
MI - Midwest	113%	11.7%	6%	8,956
OH - Midwest	106%	11.7%	5%	7,750
GA - Southeast	125%	14.8%	3%	6,814
PA - Northeast	111%	10.2%	5%	6,778
IL - Midwest	108%	9.6%	5%	6,514
NY - Northeast	113%	9.1%	4%	5,491
TN - Southeast	120%	14.1%	3%	4,958
All States¹⁷	113%	11.5%	100%	155,976

5.3 AGE AND SEX

Previous versions of this report contained exhibits comparing mortality by Sex. Since the second quarter of 2022, there has been a material increase in claims reported with a Sex of "Unknown," which distorts comparisons to the baseline period. Thus, this subsection now only contains results split by age.

For the Age segment, excess mortality for the pandemic period was also split between COVID and non-COVID claims. For example, for the 45–64 age group, the 15.9% COVID and 4.5% non-COVID total 20.4% excess mortality, which equates to the 120.4% A/E ratio since April 2020. The 65+ age band continues to have lower A/E ratios than younger age bands, and all the excess mortality for this age group (which includes retirees) can be explained by claims coded as COVID. The 0–44 age band exhibited the highest A/E ratio across the pandemic period and has

¹⁶ Includes only companies that provided Geography splits; see second bullet at the beginning of Section 5.

¹⁷ Includes only companies that provided Geography splits; see second bullet at the beginning of Section 5.

consistently shown the highest A/E by quarter since the middle of 2021. The 45–64 age band has the highest excess mortality directly attributable to COVID (15.9%), whereas the 0–44 age band has the highest excess mortality from non-COVID causes (17.7%), as shown in Table 5.7.

Table 5.7

EXCESS MORTALITY BY AGE BAND

Age	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20-6/23	% COVID	Non-COVID %	% Count
0-44	120%	130%	180%	143%	125%	120%	127%	119%	111%	122%	128%	10.7%	17.7%	8%
45-64	130%	115%	161%	142%	124%	102%	106%	106%	99%	110%	120%	15.9%	4.5%	28%
65+	120%	100%	116%	116%	113%	96%	100%	103%	96%	94%	108%	9.7%	-1.8%	64%
All Ages¹⁸	122%	107%	133%	125%	117%	99%	104%	105%	98%	101%	113%	11.5%	1.5%	100%

The greater age band detail in Table 5.8 provides further insight on excess mortality by age. The working-age population continues to see the highest A/E ratios. The 35–44 age band continues to have the highest cumulative A/E during the pandemic and has the highest non-COVID excess mortality as well. It is worth noting that "non-COVID" claims could include claims that are an indirect result of COVID, but are not coded as such in the data.

Table 5.8

EXCESS MORTALITY BY DETAILED AGE BAND

Age	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20-6/23	% COVID	Non-COVID %	% Count
0-24	101%	119%	127%	112%	99%	105%	120%	110%	100%	115%	111%	2.4%	9.1%	2%
25-34	118%	132%	179%	137%	127%	122%	131%	117%	111%	119%	128%	8.7%	19.7%	2%
35-44	129%	134%	201%	158%	135%	124%	128%	123%	116%	126%	135%	15.0%	19.9%	4%
45-54	132%	118%	179%	150%	128%	107%	112%	110%	101%	117%	125%	17.4%	8.0%	9%
55-64	129%	114%	152%	138%	122%	100%	103%	103%	97%	107%	118%	15.2%	2.7%	18%
65-74	130%	107%	130%	124%	116%	95%	99%	102%	92%	96%	112%	12.3%	-0.5%	17%
75-84	122%	105%	119%	122%	121%	102%	107%	111%	103%	101%	113%	10.1%	3.1%	20%
85+	111%	92%	104%	107%	105%	91%	94%	99%	92%	87%	102%	7.8%	-6.3%	27%
All Ages¹⁹	122%	107%	133%	125%	117%	99%	104%	105%	98%	101%	113%	11.5%	1.5%	100%

¹⁸ Includes only companies that provided Age splits; see second bullet at the beginning of Section 5.

¹⁹ Includes only companies that provided Age splits; see second bullet at the beginning of Section 5.

Tables 5.9 and 5.10 were added in the previous public report to separate out each quarter’s excess mortality by age band into the COVID and non-COVID components. These views show that the third quarter of 2021 Delta wave onset had significant excess mortality across all typical working age bands from 25 to 64, due to both COVID and non-COVID causes. The fourth quarter of 2021 continued to show very high COVID deaths in the 25 to 64 age bands, whereas the non-COVID excess mortality moderated. Starting in the second quarter of 2022, COVID deaths across all age groups have been relatively lower, but non-COVID mortality continues to be elevated in several age groups, including 25–44. Note that recent period deaths may continue to shift from non-COVID to COVID as COD coding becomes more complete.

Table 5.9

EXCESS MORTALITY BY DETAILED AGE BAND—COVID ONLY

Age	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20- 6/23
0-24	3%	2%	7%	5%	4%	1%	1%	0%	1%	0%	2%
25-34	11%	6%	35%	22%	13%	1%	1%	1%	1%	0%	9%
35-44	18%	11%	62%	41%	19%	2%	2%	2%	1%	0%	15%
45-54	28%	13%	59%	43%	27%	2%	2%	1%	1%	0%	17%
55-64	31%	11%	38%	34%	25%	2%	2%	2%	1%	0%	15%
65-74	29%	7%	21%	22%	21%	2%	3%	2%	2%	1%	12%
75-84	24%	5%	11%	14%	18%	3%	4%	3%	3%	1%	10%
85+	18%	2%	7%	8%	12%	3%	4%	4%	3%	1%	8%
All Ages²⁰	24%	7%	24%	21%	19%	2%	3%	3%	2%	0%	12%

Table 5.10

EXCESS MORTALITY BY DETAILED AGE BAND – NON-COVID ONLY

Age	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20- 6/23
0-24	98%	117%	120%	107%	95%	104%	120%	109%	100%	115%	109%
25-34	108%	126%	144%	115%	114%	121%	130%	116%	110%	119%	120%
35-44	111%	123%	139%	117%	115%	122%	125%	122%	115%	126%	120%
45-54	104%	106%	120%	107%	101%	105%	110%	108%	100%	117%	108%
55-64	98%	103%	113%	104%	98%	98%	101%	102%	96%	106%	103%
65-74	101%	100%	109%	102%	95%	93%	96%	99%	90%	96%	99%
75-84	99%	100%	108%	109%	103%	99%	103%	107%	99%	100%	103%
85+	94%	89%	98%	99%	93%	89%	90%	95%	89%	86%	94%
All Ages²¹	99%	100%	110%	104%	98%	97%	100%	102%	95%	100%	102%

²⁰ Includes only companies that provided claims split by Age; see second bullet at the beginning of Section 5.

²¹ Includes only companies that provided claims split by Age; see second bullet at the beginning of Section 5.

5.4 COMPANY SIZE

Contributing companies were assigned a size indicator of Large, Medium, or Small per the criteria described in Appendix C.2.5. Results since April 2020 have indicated higher excess mortality (and higher percentage claims identified as COVID) by decreasing company size. However, the results by Company Size are generally of the same magnitude and are usually consistent in pattern from quarter to quarter. Ratios for Large Companies have tended to be lower than those of other companies for most quarters. The spread by Company Size has narrowed since 2021, and the second quarter of 2023 is only the second quarter during the study period in which Medium companies exhibited the lowest A/E ratio (96%).

Table 5.11

EXCESS MORTALITY BY COMPANY SIZE

Co Size	2Q-4Q 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	4/20- 6/23	% COVID	% Count
Large	118%	122%	106%	131%	123%	115%	98%	102%	104%	96%	100%	112%	11.2%	79%
Medium	125%	121%	108%	139%	128%	118%	102%	105%	105%	97%	96%	115%	12.4%	16%
Small	124%	130%	111%	146%	133%	123%	102%	104%	109%	100%	108%	118%	12.7%	4%
All	119%	122%	106%	133%	125%	116%	99%	103%	104%	97%	99%	112%	11.5%	100%

Section 6: Detailed Cause of Death

Participating companies were asked to categorize claims by 15 cause of death (COD) groupings. A survey of the companies was completed prior to these requests to identify what groupings would be feasible to provide dating back to 2017. This survey, along with CDC cause of death groupings, informed the groupings presented in this report. The mapping of these COD groups can be found in Appendix E.

Approximately 30% of claims still fall into the “All Other/Unknown” group. One challenge is that three of the 20 companies were not able to provide more detailed COD information back to 2017 than what was part of the original survey, and other companies did not track one or more ICD-10 diagnosis code(s) consistently over the course of the study period, so some claims that otherwise would have been allocated to one of the new COD categories were labeled as “Unknown.”

The graphs in Figures 6.1 and 6.2 show excess mortality relative to baseline (2017–2019), ranked by the COD with the most claim counts at the top (All Other/Unknown) and the fewest at the bottom (Alzheimer’s). The graphs have been split into two parts, with the top seven CODs in the first and the bottom seven in the second. Note that the COVID-19 COD is not shown in these figures because there is no baseline mortality for COVID-19 from 2017 to 2019. Also, the 2023 incurred periods are incomplete with respect to COD; it is expected that the All Other/Unknown category will decrease in excess mortality and other categories will increase in the 2023 periods as COD reporting matures over time.

Figure 6.1

GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—TOP SEVEN CAUSES OF DEATH





Figure 6.2


GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—BOTTOM SEVEN CAUSES OF DEATH



The Committee notes that Cancer mortality rates dropped over the period of 2017–2022. Excess mortality for Accidents, both Motor Vehicle and Other, was 5%–15% higher than baseline in years 2021 and 2022. Diabetes and Liver deaths, often cited comorbidities with COVID-19 deaths, appeared to be elevated 5%–20% during much of the pandemic period. Lastly, “deaths of despair,” particularly Drug Overdose and Homicides, increased between 40%–55% and 15%–20%, respectively, during the pandemic years.

Figure 6.3 displays the COD distribution in the 2017–2019 baseline period by count. Approximately half of the 2017–2019 baseline Group Life claims were Cardiovascular or Cancer. The top 10 COD groupings (excluding All Other/Unknown) covered approximately two-thirds of all Group Life baseline claims. Although Figure 6.2 shows substantial percentage increases in the Liver, Diabetes, Drug Overdose and Homicide causes of death during the pandemic period, Figure 6.3 indicates that these causes constituted a relatively low percentage of overall deaths.

Figure 6.3
GROUP LIFE CAUSE OF DEATH DISTRIBUTION, 2017–2019 BASELINE, BY COUNT




Beginning with this iteration of the report, the Committee is including additional excess mortality graphs by cause of death that show a breakdown for three different age groupings, 0-44, 45-64, and 65-99. See Figures 6.4 through 6.9 below. These graphs mirror the graphs shown earlier in this section, but not all carriers provided age detail for claims, so the cohort of carriers used to develop these age grouping graphs represents roughly 93% of the claims used to develop those for the total claims in Figures 6.1 and 6.2. Similar to the graphs shown above, the graphs have been split into two parts, with the top seven CODs in the first and the bottom seven in the second for each of the age groupings. Also, the 2023 incurred periods are incomplete with respect to COD; it is expected that the All Other/Unknown category will decrease in excess mortality and other categories will increase in the 2023 periods as COD reporting matures over time.

Figure 6.4
GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—TOP SEVEN CAUSES OF DEATH AGES 0-44



Figure 6.5
GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—BOTTOM SEVEN CAUSES OF DEATH AGES 0-44



The Committee notes that, for the 0-44 age band, the All Other/Unknown category shows the highest excess mortality (237%²²) for the most recent quarter relative to other age bands. As noted above, as COD reporting matures over time, this excess will decrease and the excess for other categories will increase. In the top seven causes, Cardiovascular, Accidents (Motor Vehicle and Other), and Drug Overdose all appear to be meaningful contributors to the excess mortality for this age band. While Cancer appears to show some improvement, the improvement is not as pronounced as the other two age bands. For the bottom seven causes, all of the causes appear to show some material excess mortality at different points in the pandemic, but note that many of these causes have quite low death counts in the baseline period (e.g., Alzheimer's), so even a low amount of deaths can produce a fairly heightened actual-to-expected ratio.

²² To keep the scaling of the graphs consistent, the maximum percentage shown in Figure 6.4 is 185%.

Figure 6.6
GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—TOP SEVEN CAUSES OF DEATH AGES 45-64





Figure 6.7
GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—BOTTOM SEVEN CAUSES OF DEATH AGES 45-64



The Committee notes that, for the 45-64 age band, Cardiovascular, Respiratory, and Accidents (Other) appear to be noteworthy contributors to excess mortality from the top seven causes. For Cancer, unlike the 0-44 age band, the 45-64 age band shows a steady, more pronounced improvement over the course of the pandemic. For the bottom seven causes, many of the causes appear to show some material excess mortality at different points in the pandemic, but as was the case with the previous age band, many of these causes have quite low death counts in the baseline period, so even a low amount of deaths can produce a fairly heightened actual-to-expected ratio.

Figure 6.8
GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—TOP SEVEN CAUSES OF DEATH AGES 65-99





Figure 6.9
GROUP LIFE ACTUAL TO EXPECTED INCURRED MORTALITY—BOTTOM SEVEN CAUSES OF DEATH AGES 65-99



The Committee notes that, for the 65-99 age band, Accidents (Other) is the COD with the most pronounced excess among the top seven causes. Like the 45-64 age band, Cancer shows a fairly steady improvement over the course of the pandemic. Interestingly, the other CODs in the top seven (Cardiovascular, Respiratory, Cerebrovascular, and Liver) do not show the level of excess mortality seen in the other two age bands. Presumably, COVID may have displaced some of these causes of death for the 65-99 age band. As noted for the other age bands, for the bottom seven causes, the number of deaths can be somewhat low, so even a low amount of deaths can produce a fairly


heightened actual-to-expected ratio. One notable observation is that the excess mortality percentage for Drug Overdose has been high throughout the pandemic period for the 65-99 age band, despite this cause of death being typically associated with younger age groups.

Section 7: Exposure Trends

7.1 PREMIUMS

The Committee reviewed the premiums submitted for the study to determine if the premium exposure was stable or exhibited volatility during the experience period. Figure 7.1 indicates a gradual increase in premium exposure during the experience period, as expected when wage inflation is considered. Supplemental premium is growing at a faster rate and, if current trends continue, supplemental premium will become the majority in the next few years. The 2023 premiums in Figure 7.1 are reported premiums through June 2023. The overall trends in premium by year shown below are consistent, which is helpful for validating the premium data used for calculating premium per life (PPL) metrics and estimating covered lives when carriers could not provide this information.

Figure 7.1
REPORTED PREMIUM (\$ BILLIONS) BY YEAR, 2017–2023



7.2 LIVES

The Committee also reviewed life-years of exposure (LYE) reported for the study. Figure 7.2 shows LYE from 2017 through the second quarter of 2023. A slight drop in LYE occurred in 2021, possibly because of disruptions from the COVID-19 pandemic. Otherwise, basic LYE was relatively stable during the experience period, and supplemental LYE has been increasing gradually.

Figure 7.2
LIFE-YEARS OF EXPOSURE (MILLIONS) BY YEAR, 2017–2023




Table 7.1 shows average premium per LYE based on the data provided for the study along with the change from the prior year. In 2020, the average premium per LYE increased by 0.5% for Basic coverages, which is lower than any other period and likely related to the sharp increase in unemployment. Basic coverage increased significantly in the first half of 2023, which may suggest carriers are increasing rates. Supplemental has outpaced Basic in growth in most periods. 2020 and 2021 could be because consumers may have elected for additional coverage as the pandemic was at its peak.

Table 7.1
AVERAGE PREMIUM PER LIFE-YEARS OF EXPOSURE BY YEAR AND COVERAGE TYPE

Year	Average Premium per LYE		Change in Average Premium per LYE	
	Basic	Supplemental	Basic	Supplemental
2017	\$102.8	\$276.3	NA	NA
2018	\$104.8	\$280.5	1.9%	1.5%
2019	\$106.0	\$285.8	1.1%	1.9%
2020	\$106.5	\$292.3	0.5%	2.3%
2021	\$109.1	\$299.6	2.5%	2.5%
2022	\$110.4	\$305.2	1.2%	1.9%
Q1-Q2 2023	\$114.9	\$313.9	4.1%	2.9%

Table 7.2 shows average exposure per LYE and the change from the prior year. In 2021, the average exposure per LYE decreased by 1.8% for Basic coverages, but increased 0.9% for Supplemental coverages. Before 2021, the changes in average premium per LYE were limited, with most of the exposure growth coming from the Supplemental line. The 4.3% increase in the Supplemental average exposure per LYE in 2022 may be attributed to employees increasing their Supplemental benefit amounts because of the COVID-19 pandemic and above-average wage growth.

Table 7.2

AVERAGE LIFE-YEARS OF EXPOSURE BY YEAR AND COVERAGE TYPE

Year	Average LYE		Change in Average LYE	
	Basic	Supplemental	Basic	Supplemental
2017	95,408	31,454	NA	NA
2018	96,167	32,049	0.8%	1.9%
2019	97,623	32,979	1.5%	2.9%
2020	98,271	33,645	0.7%	2.0%
2021	96,535	33,943	-1.8%	0.9%
2022	99,196	35,410	2.8%	4.3%
Q1-Q2 2023	100,375	35,898	1.2%	1.4%

Section 8: Company Variations

8.1 VARIATIONS IN COVID-19 MORTALITY RESULTS

The survey showed that all participating companies had elevated Group Life mortality experience during the pandemic. However, the level of excess mortality varied between carriers. To provide insight into the dispersion of industry experience, Tables 8.1 and 8.2 provide the quartile baseline and pandemic experience, ranked by highest implied excess mortality percentage (by claim count) to lowest over the full pandemic period. The quartile incidence rates and excess mortality ratios are the weighted average of the five contributing companies' incidence rates in each quartile. In previous reports, the companies who had the highest increase in incidence also had the higher baseline incidence. This was mostly coincidental and, as we return to more normal levels of incidence, is no longer the case.

Table 8.1

QUARTERLY SEASONALLY-ADJUSTED INCURRED INCIDENCE RATES (BY COUNT)—COMPANY QUARTILES

Quartile	Baseline	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Quartile 1	2.360	2.991	3.166	2.644	2.431	2.471	2.451	2.850
Quartile 2	3.774	4.464	4.508	4.109	3.805	4.001	3.903	4.277
Quartile 3	2.870	3.365	3.438	2.905	2.550	2.510	2.530	3.114
Quartile 4	4.095	4.558	4.519	3.737	3.449	3.460	3.455	4.120
Total	3.246	3.860	3.945	3.424	3.142	3.227	3.184	3.643

Table 8.2

QUARTERLY SEASONALLY-ADJUSTED INCURRED A/E RATIOS (BY COUNT)—COMPANY QUARTILES

Quartile	Baseline	Q2 2020– Q4 2020	2021	2022	Q1 2023	Q2 2023	Q1-Q2 2023	Q2 2020– Q2 2023
Quartile 1	2.360	126.8%	134.2%	112.0%	103.0%	104.7%	103.9%	120.8%
Quartile 2	3.774	118.3%	119.4%	108.9%	100.8%	106.0%	103.4%	113.3%
Quartile 3	2.870	117.3%	119.8%	101.2%	88.9%	87.5%	88.2%	108.5%
Quartile 4	4.095	111.3%	110.4%	91.3%	84.2%	84.5%	84.4%	100.6%
Total	3.246	118.9%	121.5%	105.5%	96.8%	99.4%	98.1%	112.2%

8.2 VARIATIONS IN COVID-19 CLAIM CODING PROCEDURES

Participating carriers were asked about the data sources and procedures they used to determine whether a claim should be coded as a COVID-19 cause of death. Eighteen of the 20 carriers in the survey provided details on their claim coding procedures, and the Committee learned the following:

- Seventeen of the 18 respondents included the claim as a COVID-19 death if COVID-19 appeared anywhere on the death certificate.
- Eight of the 18 appeared to do everything in their power to research all available sources to create an exhaustive tracking of all claims where COVID was a contributing cause. These companies used five or more of the following sources to identify whether a death was caused by COVID-19:
 - Primary cause of death on death certificate
 - Secondary cause of death on death certificate
 - Claim form
 - Communication with employer or beneficiary
 - Obituary
 - Communication with medical examiner or funeral home
- One carrier coded claims with cause of COVID-19 only when COVID-19 was identified as the primary cause of death on the death certificate.
- The other nine participating carriers generally classified a death as COVID-19 if it appeared anywhere on the death certificate.

8.3 VARIATIONS IN CLAIM REPORTING PATTERNS

Appendix D.4 documents that incurred claim completion rates varied significantly from company to company. Upon analyzing the differences, the 20 contributing companies were grouped into five “reporting speed” groups based on similar reporting patterns.

The Committee investigated whether the company reporting speed groupings would be correlated to company size. However, this was not the case. The Large, Medium and Small companies are well dispersed among the five reporting speed categories.

Section 9: Comparisons to General U.S. Population Mortality Results

9.1 AGGREGATE EXCESS MORTALITY COMPARISONS

From April 2020 through June 2023, 155,834 incurred COVID claims were estimated to be in the Group Life survey data, compared with approximately 1.13 million COVID deaths in the U.S. population during the same time span according to the Centers for Disease Control and Prevention (CDC).²³

Past studies that compared insured mortality to population mortality have found that mortality among insured lives tended to be lower. In particular, the SOA's 2016 Group Term Life Mortality Study²⁴ found that, in the key working ages, insured mortality was between 30% and 40% of general population mortality. This is often considered to be a function of the fact that an employee generally is in good health to be actively at work, often has access to health care and tends to have a higher level of income (which is correlated with better health). Because the mortality rates between the two populations tend to differ, the Committee analyzed the relative impact of the COVID-19 pandemic on the Group Life data and the U.S. population by considering excess death percentages, defined as the percentage increase in mortality rate over a baseline expectation.

The excess deaths in the Group Life data were determined via a comparison to average death rates in the Group Life data from the 2017–2019 baseline, adjusted for seasonality. For the U.S. population, the Committee considered two different expectation bases. The first basis was expected deaths published by the CDC²⁵, which were developed using Farrington surveillance algorithms and historical data²⁶ (CDC method). For the second method, the Committee estimated expected deaths by computing the average CDC deaths from 2017 through 2019 and adjusting this average for changes in U.S. population size, changes in the U.S. population demographic mix by age and sex, and the trend for death rates by age group (Committee method).

Table 9.1 shows the evolution of this comparison by quarter using the Committee method for U.S. population results. The observed pattern is that the Group Life proportional excess mortality was below the U.S. population results at the start of the pandemic, then higher from the fourth quarter of 2020 through the first quarter of 2022, and then again below the U.S. population levels from the second quarter of 2022 and later.

Please note that there are some differences from numbers in the prior report. The Group Life results for periods in 2022 are now substantially more complete. For example, in the last report, we estimated excess mortality in the fourth quarter of 2022 at 5% and this now has completed to 4.2%. Due to the CDC's discontinuance of weekly summaries by sex and age, the source of information has been changed to the CDC's summaries of deaths by month, sex, and age.²⁷ This change produced only minor changes in the U.S. population numbers. Note that there are still significant completion estimates used for the first quarter of 2023, and especially for the second quarter of 2023, so these numbers may complete differently.

²³ National Center for Health Statistics, Provisional Death Counts for Coronavirus Disease 2019 (COVID-19), <https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm>.

²⁴ Society of Actuaries, 2016 Group Term Life Mortality Study & Tables, <https://www.soa.org/resources/experience-studies/2016/2016-group-life-mortality-study/>.

²⁵ National Center for Health Statistics. Excess Deaths Associated with COVID-19, https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.

²⁶ More information can be found in the technical notes on the National Center for Health Statistics website, where the CDC publishes excess deaths: https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm#techNotes.

²⁷ <https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-by-Sex-and-Age/9bhg-hcku>

Table 9.1
GROUP LIFE AND U.S. POPULATION EXCESS MORTALITY PERCENTAGES BY QUARTER

Incurred Quarter	Group Life	U.S. Population	Difference
Q1 2020	-1.4%	0.1%	-1.5%
Q2 2020	14.4%	19.8%	-5.4%
Q3 2020	14.9%	16.7%	-1.8%
Q4 2020	28.0%	25.6%	2.4%
Q1 2021	22.4%	17.0%	5.4%
Q2 2021	6.5%	4.9%	1.6%
Q3 2021	32.8%	23.3%	9.6%
Q4 2021	24.6%	18.9%	5.7%
Q1 2022	16.6%	15.3%	1.2%
Q2 2022	-1.3%	1.8%	-3.1%
Q3 2022	2.9%	7.0%	-4.1%
Q4 2022	4.2%	7.4%	-3.2%
Q1 2023	-3.2%	-1.5%	-1.7%
Q2 2023	-0.6%	-0.4%	-0.2%

9.2 EXCESS MORTALITY COMPARISON BY AGE

Most participants in the Group Life Survey provided a distribution of claims by age, but were not able to provide a distribution of exposure by age. For this reason, the comparisons below show claim counts unadjusted by any changes in exposure by age. The seasonality adjustment, which was determined in aggregate for all ages, has also been removed to show a more direct comparison. Removing the seasonal adjustment does produce slightly different excess ratios than what was reported above in Table 5.7.

Table 9.2 shows the actual-to-baseline ratios by broad age group. These excess percentages have been adjusted for overall changes in exposure, but not for seasonal differences, either in total or by age.

Please note that the prior version of this report also had segmentation by sex, but we have seen a much higher proportion of claims submitted with an unknown sex. These deaths with unknown sex are disproportionately from older-aged claims so, when segmenting by age, we see artificially low mortality levels at the older ages. For this reason, we have dropped this segment.

Since not all carriers supply age, the “All Ages” results will differ slightly from the totals elsewhere in this report.

Table 9.2
EXCESS DEATH PERCENTAGES BY BROAD AGE GROUP²⁸

Age	Population	Q2-Q4 2020	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
15-44	Group Life	21.6%	42.9%	31.8%	17.0%	22.4%	20.8%	16.7%	18.9%
15-44	U.S. Pop.	29.0%	40.7%	31.7%	22.4%	26.7%	24.4%	16.9%	19.2%
15-44	Difference	-7.4%	2.2%	0.2%	-5.4%	-4.2%	-3.5%	-0.1%	-0.3%
45-64	Group Life	21.3%	37.0%	30.9%	-0.3%	2.0%	7.3%	3.3%	7.5%
45-64	U.S. Pop.	19.1%	26.1%	24.9%	0.3%	2.1%	7.0%	0.7%	-4.0%
45-64	Difference	2.3%	10.9%	6.0%	-0.6%	-0.1%	0.3%	2.6%	11.5%
65-99	Group Life	14.9%	13.1%	18.8%	-6.7%	-4.5%	4.9%	0.2%	-8.4%
65-99	U.S. Pop.	21.0%	16.6%	28.2%	1.9%	5.1%	15.7%	11.9%	1.7%
65-99	Difference	-6.1%	-3.6%	-9.3%	-8.7%	-9.6%	-10.9%	-11.8%	-10.1%
All Ages	Group Life	17.2%	22.1%	23.2%	-3.0%	-0.5%	6.8%	2.4%	-1.8%
All Ages	U.S. Pop.	21.1%	19.9%	27.7%	2.9%	5.8%	14.6%	10.0%	1.7%
All Ages	Difference	-3.9%	2.2%	-4.5%	-5.9%	-6.3%	-7.7%	-7.7%	-3.5%

When considering the totals by age, the Group Life population generally has better experience than the U.S. population at the younger and older ages while, in the age band from 45-64, the U.S. population has better experience than the Group Life population except in the second quarter of 2022.

Note also that the 2023 Group Life results were as of June 30, 2023 and, therefore, include a significant completion assumption. This assumption is determined in aggregate and may not be appropriate by age. For example, the Committee suspects that deaths for younger ages are reported more quickly than for older ages and, thus, the 2023 results will likely not end up as unfavorable for the 15-44 age band. However, the 2022 results are fairly complete and still show significantly lower excess mortality for the older ages.

One of the observations from both the Group Life Survey and the U.S. population results is that the deaths were higher than expected through the first quarter of 2022 for all age groups and have remained higher than expected for the 15-44 age group, even after excluding explicit COVID-19 deaths. This comparison is captured in Table 9.3

²⁸ Because there are an immaterial amount of 0-14 year-olds in the Group Life population, the U.S. population ages 15-44 is used for comparison. For consistency, the Group Life population uses the same age range label. For the U.S. population "All Ages" row, ages 0-14 are excluded.

Table 9.3
EXCESS DEATH PERCENTAGES, EXCLUDING COVID-19, BY BROAD AGE GROUP

Age	Population	Q2-Q4 2020	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
15-44	Group Life	13.0%	20.0%	17.9%	15.4%	20.9%	19.7%	15.9%	18.8%
15-44	U.S. Pop.	22.5%	27.2%	18.8%	20.6%	24.3%	22.6%	15.5%	18.7%
15-44	Difference	-9.5%	-7.2%	-0.9%	-5.2%	-3.4%	-2.9%	0.4%	0.0%
45-64	Group Life	5.0%	6.4%	6.4%	-1.9%	0.0%	5.8%	2.1%	7.0%
45-64	U.S. Pop.	5.0%	6.0%	2.5%	-2.1%	-1.4%	4.3%	-1.6%	-4.9%
45-64	Difference	0.1%	0.4%	3.9%	0.2%	1.4%	1.5%	3.7%	11.9%
65-99	Group Life	0.4%	0.2%	3.0%	-9.1%	-8.2%	1.7%	-2.7%	-9.2%
65-99	U.S. Pop.	3.5%	3.4%	7.2%	-1.6%	-1.0%	10.3%	6.8%	-0.1%
65-99	Difference	-3.1%	-3.2%	-4.2%	-7.4%	-7.2%	-8.6%	-9.5%	-9.1%
All Ages	Group Life	2.7%	3.5%	5.1%	-5.1%	-3.6%	4.3%	0.2%	-2.4%
All Ages	U.S. Pop.	4.9%	5.4%	7.0%	-0.4%	0.5%	9.9%	5.7%	0.1%
All Ages	Difference	-2.2%	-1.8%	-1.9%	-4.7%	-4.0%	-5.6%	-5.6%	-2.6%

For the older ages, the Group Life and U.S. population deaths, excluding COVID-19, were below expectations starting in the second quarter of 2022 and forward, except for the fourth quarter of 2022. The Group Life experience also is proportionally worse in ages 45-64, but otherwise somewhat better than the U.S. population at younger and older ages. The larger differences in the second quarter of 2023 should be considered unsettled due to the importance of the completion assumptions.

To visualize the differences by age over time, Figures 9.1 through 9.6 show ratios of actual total and non-COVID deaths to baseline expectations by month and age group. Results in the second quarter of 2023 should be considered uncertain.

Figure 9.1
EXCESS DEATH PERCENTAGES ALL DEATHS, UNDER AGE 45




Figure 9.2
EXCESS DEATH PERCENTAGES EXCLUDING COVID-19, UNDER AGE 45




Figure 9.3
EXCESS DEATH PERCENTAGES ALL DEATHS, AGES 45-64




Figure 9.4
EXCESS DEATH PERCENTAGES EXCLUDING COVID-19, AGES 45-64




Figure 9.5
EXCESS DEATH PERCENTAGES ALL DEATHS, AGES 65 AND OVER





Figure 9.6
EXCESS DEATH PERCENTAGES EXCLUDING COVID-19, AGES 65 AND OVER



For older ages, the Group Life experience has been consistently better than the U.S. population throughout the pandemic, with the gap widening in recent periods. For ages 45-64, the experience is quite consistent between the two populations. The divergence in the second quarter of 2023 is likely due to completion uncertainty.

The Committee looked at the effect that the different age distributions had on the relationship between the U.S. population and Group Life results. The Committee compared actual total excess deaths for the U.S. population to what the total excess deaths would have been had the distribution of claims by age matched what we observed for Group Life. This produced very little difference in the total excess, meaning that age distribution alone does not explain much of the difference in excess mortality between the two populations over time.

9.3 EXCESS MORTALITY COMPARISON BY CAUSE OF DEATH

Carriers were asked to provide 15 different causes of death, including COVID-19. The CDC provides detailed causes of death (ICD-10 Codes), which can be mapped to the 15 Group Life CODs using the definitions listed in appendix E.

Using information furnished by the Group Life survey participants and the CDC, the Committee investigated differences in excess mortality by cause of death. Both the CDC and Group Life datasets tended to have a high level of unknown causes for more recent deaths because it often takes time to investigate the actual causes. The CDC suppresses deaths due to external causes for six months to allow time to do a full assessment. For this reason, this section includes only deaths through the end of 2022.

Seasonality can be very important for causes of death, so rather than rely on the overall seasonal adjustments described earlier in this report, the Committee compared deaths in the years 2020–2022 to the same months in the baseline period. For example, the first quarter of 2021 was compared to the average from the first quarters of the years 2017 through 2019.

Table 9.4 compares the causes of deaths between the two populations. These excess percentages have been adjusted for overall changes in exposure, but not for seasonal differences, either in total or by diagnosis.

Table 9.4
GROUP LIFE AND U.S. POPULATION EXCESS MORTALITY PERCENTAGES BY QUARTER, ALL AGES

Cause of Death	Baseline Percent of Claims		Percent Change in Claim Counts					
			2020		2021		2022	
	Group Life	U.S. CDC	Group Life	U.S. CDC	Group Life	U.S. CDC	Group Life	U.S. CDC
All Other / Unknown	31.1%	23.2%	7.5%	9.7%	9.9%	10.7%	11.4%	23.0%
Major Cardiovascular Diseases	26.5%	23.1%	1.9%	5.4%	1.6%	4.6%	-4.3%	4.8%
Cancer	22.9%	21.1%	-4.5%	-0.6%	-6.0%	-0.6%	-13.0%	-1.0%
Respiratory	6.9%	7.8%	-1.7%	-3.5%	-4.4%	-7.6%	-7.1%	-5.3%
Accidents (non-motor vehicle)	3.0%	3.2%	9.3%	7.8%	14.7%	15.3%	12.5%	6.7%
Suicide	2.2%	1.7%	-5.8%	-4.6%	0.2%	-0.5%	-4.2%	0.3%
Accidents (motor vehicle)	1.9%	1.4%	-0.1%	5.5%	10.7%	16.8%	5.4%	8.9%
Cerebrovascular, including stroke	1.8%	5.2%	2.6%	7.1%	-3.7%	8.2%	-13.1%	8.9%
Liver	1.1%	1.5%	3.9%	18.8%	14.8%	29.5%	5.7%	24.4%
Drug Overdose	0.6%	1.8%	44.4%	40.5%	56.8%	65.1%	41.9%	57.3%
Diabetes	0.6%	3.0%	23.0%	18.4%	4.9%	19.0%	4.3%	15.7%
Influenza & Pneumonia	0.6%	1.9%	14.6%	-3.4%	-3.8%	-24.8%	-17.4%	-17.5%
Homicide	0.6%	0.7%	18.1%	27.3%	19.1%	34.0%	16.4%	21.8%
Alzheimer's	0.2%	4.3%	32.1%	9.2%	2.4%	-3.4%	-2.7%	-3.4%
Total Excluding COVID-19	100.0%	100.0%	2.6%	5.4%	3.0%	5.3%	-0.6%	7.5%
COVID-19	0.0%	0.0%	11.2%	12.2%	18.6%	14.5%	6.3%	6.4%
Total	100.0%	100.0%	13.8%	17.6%	21.6%	19.7%	5.7%	13.8%

There is no baseline expectation for COVID-19, so these are compared to the total deaths across all causes. The causes are sorted by total baseline claims for Group Life. The All Other/Unknown category is a larger percentage of the overall deaths for Group Life because some carriers were not able to provide all causes of death consistently back to 2017, as described in Section 6. All U.S. population deaths have an established cause, except for those listed as ill-defined (ICD-10 R99). The higher proportion in the category in 2022 are likely still due to deaths for which the cause has not yet been established.

There are some differences between the distribution of excess death causes between the two sources. Group Life excess deaths are generally lower for drug overdose, liver disease, cerebrovascular, major cardiovascular diseases, homicides and cancer, and relatively higher for Alzheimer's, non-motor vehicle accidents, and flu and pneumonia.

The percentage change can be misleading because a high percentage increase can be caused by relatively few excess deaths when the overall death level in the category is small. Table 9.5 gives a similar view, except that the excess deaths for each cause are divided by the total baseline death expectations. For example, in the Group Life data, the excess deaths due to major cardiovascular disease in 2021 were 0.5% of the baseline expectation.

Table 9.5
GROUP LIFE AND U.S. POPULATION EXCESS MORTALITY PERCENTAGES BY QUARTER

Cause of Death	Baseline Percent of Claims		Number of Excess Deaths Divided by Total Baseline					
			2020		2021		2022	
	Group Life	U.S. CDC	Group Life	U.S. CDC	Group Life	U.S. CDC	Group Life	U.S. CDC
All Other / Unknown	31.1%	23.2%	2.3%	2.3%	3.1%	2.5%	3.5%	5.3%
Major Cardiovascular Diseases	26.5%	23.1%	0.5%	1.2%	0.4%	1.1%	-1.1%	1.1%
Cancer	22.9%	21.1%	-1.0%	-0.1%	-1.4%	-0.1%	-3.0%	-0.2%
Respiratory	6.9%	7.8%	-0.1%	-0.3%	-0.3%	-0.6%	-0.5%	-0.4%
Accidents (non-motor vehicle)	3.0%	3.2%	0.3%	0.3%	0.4%	0.5%	0.4%	0.2%
Suicide	2.2%	1.7%	-0.1%	-0.1%	0.0%	0.0%	-0.1%	0.0%
Accidents (motor vehicle)	1.9%	1.4%	0.0%	0.1%	0.2%	0.2%	0.1%	0.1%
Cerebrovascular, including stroke	1.8%	5.2%	0.0%	0.4%	-0.1%	0.4%	-0.2%	0.5%
Liver	1.1%	1.5%	0.0%	0.3%	0.2%	0.4%	0.1%	0.4%
Drug Overdose	0.6%	1.8%	0.3%	0.7%	0.3%	1.2%	0.3%	1.0%
Diabetes	0.6%	3.0%	0.1%	0.6%	0.0%	0.6%	0.0%	0.5%
Influenza & Pneumonia	0.6%	1.9%	0.1%	-0.1%	0.0%	-0.5%	-0.1%	-0.3%
Homicide	0.6%	0.7%	0.1%	0.2%	0.1%	0.2%	0.1%	0.1%
Alzheimer's	0.2%	4.3%	0.1%	0.4%	0.0%	-0.1%	0.0%	-0.1%
Total Excluding COVID-19	100.0%	100.0%	2.6%	5.4%	3.0%	5.3%	-0.6%	7.5%
COVID-19	0.0%	0.0%	11.2%	12.2%	18.5%	14.5%	6.3%	6.4%
Total	100.0%	100.0%	13.8%	17.6%	21.6%	19.7%	5.7%	13.8%

Aside from COVID-19, we see that All Other/Unknown is the largest contributor to excess deaths in all three years and for both populations. The Committee does not have any details on these claims from the Group Life survey, but these details are available for the U.S. population (see Table 9.6 below).

The next-largest contributor to excess deaths has generally been major cardiovascular disease, with the exception of the experience for the Group Life population in 2022, when this COD had deaths below baseline. The increase in drug overdoses is more significant within the U.S. population than Group Life, whereas liver disease (cirrhosis) is elevated in both populations. Diabetes deaths are elevated in both populations, but represent a much smaller proportion of deaths for Group Life. Non-motor vehicle accidents are elevated in all years and in both populations.

To help visualize the dynamics, Figures 9.7 through 9.12 show deaths relative to the baseline by cause and month for the two populations. The deaths are compared to the same month in the baseline period. Since many causes of death on recent deaths remain unknown, the charts show results up through the end of 2022.

Figure 9.7
DEATHS RELATIVE TO BASELINE—MAJOR CARDIOVASCULAR DISEASE






Figure 9.7 shows that, during 2022, there was a significant drop-off in cardiovascular deaths in the Group Life population, while the U.S. population still shows excess mortality from this cause comparable to that seen in 2020 and 2021.

Figure 9.8
DEATHS RELATIVE TO BASELINE—DRUG OVERDOSES



Drug overdoses remain significantly elevated in both populations. Note that, while the proportional increases are similar, overdoses comprise a higher percentage of total deaths in the U.S. population, so the excess is more meaningful for this group.

Figure 9.9
DEATHS RELATIVE TO BASELINE—ALL OTHER/UNKNOWN



These deaths show a similar pattern of increase. Note that, for the Group Life data, there are claims where the cause is not known, whereas most of the U.S. population deaths are from causes that do not fall into the other categories.

Figure 9.10
DEATHS RELATIVE TO BASELINE—LIVER DISEASE




Figure 9.10 shows that the proportional impact of liver disease was more significant for the U.S. population than for Group Life.

Figure 9.11
DEATHS RELATIVE TO BASELINE—DIABETES




Figure 9.11 shows that, in 2021 and 2022, there was considerably higher excess mortality from diabetes in the U.S. population than the Group Life population.

Figure 9.12
DEATHS RELATIVE TO BASELINE—CANCER




Figure 9.12 shows cancer declining fairly significantly during the pandemic period for Group Life, but not for the U.S. population.

Since the All Other/Unknown category is significantly elevated, the Committee researched the most prominent ICD-10 codes that make up this group in the U.S. population. Table 9.6 shows the top 20 codes for excess deaths, sorted by excess deaths in 2020 and 2021. 2022 and 2023 were not included because the cause for some deaths may not yet be determined.

Table 9.6
U.S. POPULATION EXCESS MORTALITY BY ICD-10 CODE FOR “ALL OTHER/UNKNOWN”

ICD-10 Description	Excess Deaths	
	2020	2021
Senile degeneration of brain, not elsewhere classified	13,589	18,480
Parkinson’s disease	6,538	4,807
Essential (primary) hypertension	3,931	4,237
Unspecified severe protein-energy malnutrition	2,821	4,631
Hyperlipidemia, unspecified	3,136	4,007
Vascular dementia, unspecified	3,355	2,641
Mental and behavioral disorders due to use of alcohol, harmful use	2,117	2,827
Mental and behavioral disorders due to use of alcohol, dependence syndrome	2,063	2,631
Hypertensive renal disease with renal failure	1,822	2,290
Unspecified protein-energy malnutrition	1,692	2,294
Chronic kidney disease, stage 5	1,616	2,107
Metabolic disorder, unspecified	1,090	2,046
Urinary tract infection, site not specified	902	1,975
Other obesity	1,246	1,547
Coronavirus infection, unspecified	1,887	708
Obesity, unspecified	972	1,586
Other specified degenerative diseases of nervous system	1,375	1,136
Acute renal failure, unspecified	395	2,097
Gastrointestinal hemorrhage, unspecified	1,009	1,405
Fatty (change of) liver, not elsewhere classified	796	1,229

Many of these conditions appear to be due to general poor health that may have been exacerbated by COVID-19.

9.3 EXCESS MORTALITY COMPARISON BY GEOGRAPHIC REGION

The CDC method described above for U.S. population expected deaths enables a comparison of excess death percentages by month and geographic region. Tables 9.7 and 9.8 display the excess death percentages by quarter and region for the U.S. population and the Group Life survey data, respectively. The “Total Excl. Other” row shows the weighted average A/E ratio for claims that could be allocated to the four regions.

Table 9.7

U.S. POPULATION EXCESS DEATH PERCENTAGE BY QUARTER AND GEOGRAPHIC REGION

Region	Q2–Q4 2020	2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q2 2020– Q2 2023	% of Total COVID Deaths
Midwest	20.9%	12.7%	19.3%	-0.4%	4.4%	8.1%	-0.5%	-0.9%	10.9%	21.2%
Northeast	25.0%	11.2%	17.6%	-0.1%	3.7%	7.7%	0.8%	-2.1%	11.3%	21.4%
Southeast	20.6%	22.6%	23.1%	2.7%	9.8%	8.7%	3.7%	0.6%	15.2%	38.1%
West	18.7%	20.7%	21.0%	3.6%	11.3%	12.8%	5.0%	2.3%	14.9%	19.3%
Total Excl. Other	21.2%	17.7%	20.7%	1.6%	7.6%	9.2%	2.5%	0.0%	13.4%	99.4%
Total	21.1%	17.6%	20.7%	1.7%	7.7%	9.2%	2.5%	0.1%	13.4%	100.0%

Table 9.8


GROUP LIFE COVID-19 SURVEY EXCESS DEATH PERCENTAGE BY QUARTER AND GEOGRAPHIC REGION

Region	Q2–Q4 2020	2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q2 2020– Q2 2023	% of Total COVID Deaths
Midwest	18.0%	15.3%	16.9%	-3.2%	1.7%	3.1%	-5.6%	6.2%	10.3%	26.2%
Northeast	23.5%	17.4%	18.7%	2.1%	0.1%	8.1%	0.5%	-0.5%	13.0%	17.6%
Southeast	19.8%	31.7%	17.8%	-1.1%	7.0%	5.6%	-0.7%	4.1%	16.8%	41.0%
West	19.4%	23.4%	14.2%	1.3%	3.8%	3.7%	-3.8%	-13.9%	12.1%	15.3%
Total Excl. Other	20.0%	22.8%	17.2%	-0.6%	3.5%	5.1%	-2.3%	0.9%	13.4%	99.6%
Total	19.0%	21.6%	16.2%	-1.3%	2.9%	4.2%	-3.2%	-0.6%	12.4%	100.0%

Figure 9.13 shows excess death percentages by region for both the Group Life data and the U.S. population data.

Figure 9.13

EXCESS DEATH PERCENTAGES BY GEOGRAPHIC REGION, APRIL 2020 THROUGH JUNE 2023



For the April 2020 through June 2023 period, the Southeast showed the highest excess mortality for both the Group Life data and the U.S. population. The Midwest experienced the lowest excess mortality for both datasets during the pandemic period, though significant variations by season have been seen. For the Group Life data, the Southeast was the only region with higher-than-average excess mortality. The largest contrast between the Group Life data and the U.S. population data was in the West, where the U.S. population has excess mortality 2.8% (additive) higher than the U.S. population.

Section 10: Reliance and Limitations

In producing this report, the Committee relied upon data furnished by contributing companies and data published by the CDC. The Committee would like to stress that the data presented in this survey are emerging. Contributing companies may true up these data over time. The Committee also notes that carriers submitted data in different formats; it is possible that the homogenization of data submissions could introduce some unintended distortion in the survey results. The reader should review the limitations noted throughout the report.



Give us your feedback!

Take a short survey on this report.

[Click Here](#)

 **SOA**
Research
INSTITUTE

Section 11: List of Participating Companies

The Committee would like to thank the following companies that submitted data and made this COVID-19 mortality survey possible:

Aflac
Dearborn National
Elevance
Guardian
The Hartford
Lincoln Financial Group
MetLife
Mutual of Omaha
New York Life Group Benefit Solutions
OneAmerica
Principal Financial
Reliance Standard
Renaissance
Securian Financial Group
Standard Insurance Group
SunLife Financial Group
Symetra
Unum
USABLE
Voya

Appendix A: 2020 SOA Group Term Life COVID-19 Mortality Survey Data Request

Purpose

This is the data request for a Group Term Life Claim study intended to allow a quick assessment of the impact of the COVID-19 pandemic on the Group Life industry—primarily by measuring the extra mortality occurring during the pandemic as compared to prior periods. This high-level study will become a valuable data source for Group Life insurers, since the industry wide COVID-19 claims will be significantly more credible than the claims experience for any one carrier.

Timing

We are requesting the initial data submission be provided by **Friday, June 19th**. We acknowledge that this is a tight turnaround, but due to the rapidly changing environment, time is of the essence. Please let us know ASAP if you have a problem with this date or any element of this request. We plan to act quickly on the data—releasing an initial summary report to participating carriers the week of July 6th.

The initial data request is for data from January 2017 through May 2020. We also plan to update the study monthly throughout the duration of the pandemic. Please consider this when you build your queries for the initial request, so that the monthly updates are easier to produce. We request that updates be submitted by the 3rd Friday of each month. Contributors will receive a detailed summary report of their submitted data with some analysis of all the contributed data after each monthly submission. The SOA will also be releasing summary reports of the aggregated results periodically throughout the duration of the study.

General Comments

Our goal is to measure patterns and trends rather than actual mortality rates. For the data request, this means we are more interested in how things change by month than whether they are 100% accurate or even consistent with other carrier submissions. We understand this data assembly will take some effort, and want to minimize unnecessary data manipulation. To this end, please develop your submission as best you can to align with our request, but more importantly, please ensure it is consistent over subsequent monthly updates.

Claim Data Request

Broadly, we are requesting summarized death claim information for your group life business with limited segmentation. The limited segmentation will support further analysis/validation of observed trends. We hope all carriers will be able to provide the Baseline data below. Please also provide the Segmentation if feasible, but we can include your submission in the study even if these components are not readily available.

1. Baseline—The essential data requested is claim counts by incurred month, reported month, product segment, and limited cause of death. Ideally, claim amounts can also be provided.
 - Product Segment = Basic Life, Supp/Optional/Voluntary Life, and Retiree Life
 - Cause of Death = COVID, Accident, and All Other

2. Segmentation—We are also requesting claim counts and amounts for three separate segments—industry, state, and age/sex. Data for each requested segment would be further split into the product and cause of death categories referenced above.
 - Industry = 2-digit SIC code is ideal
 - State = Based on residence, or work location if residence not available
 - Age/Sex = M/F/U, and 10-year age bands

Claim Data Specifics

Again, as we will be looking at trends and patterns rather than actual mortality, it is most important that your submission be consistent month to month. Nevertheless, the ideal submission should consider the following specific criteria:

- Include only group term life business. Exclude any GUL/GVUL, COLI/BOLI, 10/20-year group term, etc.
- Include both self-administered and list-billed business
- Include employee, spouse, and child claims
- Include or exclude portability and conversion claims—whichever is easier—based on your company reporting.
- Include deaths from persons on waiver of premium; exclude active waivers
- Include only death claims; exclude counts or amounts for various riders, especially living benefit riders or critical illness riders
- Include only the life insurance amount for accidental deaths
- Exclude any interest payments or expenses

Exposure Data Request

As stated, this is not a mortality rate study, and we do not intend to calculate mortality rates. The purpose of exposure data is to help explain and validate any observed trends. As with claims, we are requesting both high-level exposure data, as well as exposure data by segment. However, the most critical information is exposures by month.

1. Baseline—The essential data requested is earned premium by report month and product segment. Optional data would include exposed lives by month.
 - Product Segment = Basic Life, Supp/Optional/Voluntary Life, and Retiree Life
2. Segmentation—We are also requesting exposure data for the segments—industry, state, and age/sex. Data for each requested segment would be further split by product.
 - Industry = 2-digit SIC code is ideal
 - State = Based on residence, or work location if residence not available
 - Age/Sex = M/F/U, and 10-year age bands

Exposure Data Specifics

We recognize that it can be difficult to provide exposed lives data, which is why we have selected earned premium as the primary exposure metric. Exposed lives is certainly a valuable addition if it is available. As with claims, we stress the importance of consistency month to month, and reiterate that we are interested in the information you can provide with relative ease. Some specific (ideal) considerations include:

- Include only group term life business. Exclude any GUL/GVUL, COLI/BOLI, 10/20-year group term, etc.
- Include or exclude premium for accident riders depending on how they are handled in your system; just be consistent and identify what is included.
- Include both self-administered and list-billed business.
- For exposed lives, we recognize that some data (list billed groups, for example) may be more current and accurate than other data. Please provide your best representation of exposed lives, and identify any particular limitations or special considerations in your submission.

Final Notes on Requested Data

We intend to turn around results rapidly to maximize value on internal decision-making for participating carriers. With that in mind, we have tried to keep the request as simple as possible. We have tried to define exactly what we are requesting, but if your own tracking does not align and the customization is difficult, then please provide what you normally track rather than trying to match our definitions. The period-over-period change will be most valuable,

so consistency is more important than precise definitions. We understand there can be nuances in how carriers count claims and track exposures, but we think the recently observed changes will be valuable. If you have any questions at all about what we are asking, please reach out.

PLEASE NOTE: YOUR DATA SUBMISSIONS SHOULD NOT CONTAIN ANY INDIVIDUAL POLICY LEVEL INFORMATION. PLEASE SEND ONLY THE AGGREGATED SUMMARY INFORMATION REQUESTED.

SOA staff will be receiving and compiling your submissions and the SOA is not able to receive any personal information on your policyholders.

Reports

Our minimal request is for the monthly results without industry, geographic, or demographic segmentation. Please provide the additional segment data as you are able, and we will return cross-industry information consistent with your submission. We do not plan to provide individual carrier-level experience.

We plan to show cross-industry extra mortality by calendar month. We will compare the most recent months to the prior periods, including prior months, and the same month a year ago.

We will not show individual carrier experience, but may comment on the consistencies of changes across carriers.

Technical Notes

The accompanying Excel workbook contains specific templates for the data submission. You can use the Excel templates or submit data in a format of your choosing. The workbook includes an “Outline” tab to guide your submission.

Please return the submission via e-mail to Korrel Crawford at kcrawford@soa.org. If you have concerns about file security, please contact her and she will provide you with an alternate means of submitting data in a more secure fashion.

Appendix B: Geography and Industry Code Mappings

Table B.1

GEOGRAPHY CODE MAPPINGS

Abbreviation	State/Province Name	Division	Region
AA	U.S. Armed Forces–Americas	Division 11: Unknown	Other
AB	Alberta	Division 10: Canada	Other
AE	U.S. Armed Forces–Europe	Division 11: Unknown	Other
AK	Alaska	Division 09: Pacific	West
AL	Alabama	Division 06: East South Central	Southeast
AP	U.S. Armed Forces–Pacific	Division 11: Unknown	Other
AR	Arkansas	Division 07: West South Central	Southeast
AS	American Samoa	Division 09: Pacific	Other
AZ	Arizona	Division 08: Mountain	West
BC	British Columbia	Division 10: Canada	Other
CA	California	Division 09: Pacific	West
CO	Colorado	Division 08: Mountain	West
CT	Connecticut	Division 01A: Southern New England	Northeast
DC	District of Columbia	Division 02: Middle Atlantic	Northeast
DE	Delaware	Division 02: Middle Atlantic	Northeast
FL	Florida	Division 05: South Atlantic	Southeast
FM	Micronesia	Division 09: Pacific	Other
GA	Georgia	Division 05: South Atlantic	Southeast
GU	Guam	Division 09: Pacific	Other
HI	Hawaii	Division 09: Pacific	West
IA	Iowa	Division 04: North Central	Midwest
ID	Idaho	Division 08: Mountain	West
IL	Illinois	Division 03: Great Lakes	Midwest
IN	Indiana	Division 03: Great Lakes	Midwest
KS	Kansas	Division 04: North Central	Midwest
KY	Kentucky	Division 06: East South Central	Southeast
LA	Louisiana	Division 07: West South Central	Southeast
MA	Massachusetts	Division 01A: Southern New England	Northeast
MB	Manitoba	Division 10: Canada	Other
MD	Maryland	Division 02: Middle Atlantic	Northeast
ME	Maine	Division 01B: Northern New England	Northeast
MH	Marshall Islands	Division 09: Pacific	Other
MI	Michigan	Division 03: Great Lakes	Midwest
MN	Minnesota	Division 04: North Central	Midwest
MO	Missouri	Division 04: North Central	Midwest
MP	Northern Mariana Islands	Division 09: Pacific	Other
MS	Mississippi	Division 06: East South Central	Southeast
MT	Montana	Division 08: Mountain	West

Abbreviation	State/Province Name	Division	Region
NB	New Brunswick	Division 10: Canada	Other
NC	North Carolina	Division 05: South Atlantic	Southeast
ND	North Dakota	Division 04: North Central	Midwest
NE	Nebraska	Division 04: North Central	Midwest
NH	New Hampshire	Division 01B: Northern New England	Northeast
NJ	New Jersey	Division 02: Middle Atlantic	Northeast
NL	Newfoundland and Labrador	Division 10: Canada	Other
NM	New Mexico	Division 08: Mountain	West
NS	Nova Scotia	Division 10: Canada	Other
NU	Nunavut	Division 10: Canada	Other
NV	Nevada	Division 08: Mountain	West
NW	Northwest Territories	Division 10: Canada	Other
NY	New York	Division 02: Middle Atlantic	Northeast
OH	Ohio	Division 03: Great Lakes	Midwest
OK	Oklahoma	Division 07: West South Central	Southeast
ON	Ontario	Division 10: Canada	Other
OR	Oregon	Division 09: Pacific	West
Other	Other	Division 11: Unknown	Other
PA	Pennsylvania	Division 02: Middle Atlantic	Northeast
PE	Prince Edward Island	Division 10: Canada	Other
PR	Puerto Rico	Division 05: South Atlantic	Other
PW	Palau	Division 09: Pacific	Other
QC	Quebec	Division 10: Canada	Other
RI	Rhode Island	Division 01A: Southern New England	Northeast
SC	South Carolina	Division 05: South Atlantic	Southeast
SD	South Dakota	Division 04: North Central	Midwest
SK	Saskatchewan	Division 10: Canada	Other
TN	Tennessee	Division 06: East South Central	Southeast
TX	Texas	Division 07: West South Central	Southeast
UN	Unknown	Division 11: Unknown	Other
Unknown	Unknown	Division 11: Unknown	Other
UT	Utah	Division 08: Mountain	West
VA	Virginia	Division 05: South Atlantic	Southeast
VI	U.S. Virgin Islands	Division 05: South Atlantic	Other
VT	Vermont	Division 01B: Northern New England	Northeast
WA	Washington	Division 09: Pacific	West
WI	Wisconsin	Division 03: Great Lakes	Midwest
WV	West Virginia	Division 02: Middle Atlantic	Northeast
WY	Wyoming	Division 08: Mountain	West
YK	Yukon	Division 10: Canada	Other

Table B.2
INDUSTRY CODE MAPPINGS

Two-Digit Standard Industrial Code	Industry Group	Collar Color
00	Unknown/Invalid	Unknown
01	Agricultural; Forestry; Fishing	Blue
02	Agricultural; Forestry; Fishing	Blue
03	Agricultural; Forestry; Fishing	Blue
04	Agricultural; Forestry; Fishing	Blue
05	Agricultural; Forestry; Fishing	Blue
07	Agricultural; Forestry; Fishing	Blue
08	Agricultural; Forestry; Fishing	Blue
09	Agricultural; Forestry; Fishing	Blue
10	Mining	Blue
11	Mining	Blue
12	Mining	Blue
13	Mining	Blue
14	Mining	Blue
15	Construction	Blue
16	Construction	Blue
17	Construction	Blue
18	Construction	Blue
19	Construction	Blue
20	Manufacturing—Food	Blue
21	Manufacturing—Food	Blue
22	Manufacturing—Clothes; Textile; Wood	Blue
23	Manufacturing—Clothes; Textile; Wood	Blue
24	Manufacturing—Clothes; Textile; Wood	Blue
25	Manufacturing—Clothes; Textile; Wood	Blue
26	Manufacturing—Clothes; Textile; Wood	Blue
27	Manufacturing—Paper; Drugs	Gray
28	Manufacturing—Paper; Drugs	Gray
29	Manufacturing—Paper; Drugs	Gray
30	Manufacturing—Paper; Drugs	Gray
31	Manufacturing—Paper; Drugs	Gray
32	Manufacturing—Paper; Drugs	Gray
33	Manufacturing—Heavy; Steel	Blue
34	Manufacturing—Heavy; Steel	Blue
35	Manufacturing—Heavy; Steel	Blue
36	Manufacturing—Heavy; Steel	Blue
37	Manufacturing—Auto, Airplanes, Precision Equipment	Blue
38	Manufacturing—Auto, Airplanes, Precision Equipment	Blue
39	Manufacturing—Auto, Airplanes, Precision Equipment	Blue

Two-Digit Standard Industrial Code	Industry Group	Collar Color
40	Transport; Communication; Utilities	Blue
41	Transport; Communication; Utilities	Blue
42	Transport; Communication; Utilities	Blue
43	Transport; Communication; Utilities	Blue
44	Transport; Communication; Utilities	Blue
45	Transport; Communication; Utilities	Blue
46	Transport; Communication; Utilities	Blue
47	Transport; Communication; Utilities	Blue
48	Transport; Communication; Utilities	Blue
49	Transport; Communication; Utilities	Blue
50	Wholesale Trade	Gray
51	Wholesale Trade	Gray
52	Retail—Trade	Gray
53	Retail—Trade	Gray
54	Retail—Trade	Gray
55	Retail—Trade	Gray
56	Retail—Trade	Gray
57	Retail—Trade	Gray
58	Retail—Trade	Gray
59	Retail—Trade	Gray
60	Banks and Securities	White
61	Banks and Securities	White
62	Banks and Securities	White
63	Insurance; Other Finance	White
64	Insurance; Other Finance	White
65	Insurance; Other Finance	White
66	Insurance; Other Finance	White
67	Insurance; Other Finance	White
68	Insurance; Other Finance	White
69	Insurance; Other Finance	White
70	Hotels/Personal Services	Grey
71	Hotels/Personal Services	Grey
72	Hotels/Personal Services	Grey
73	Misc. Service/Data Processing	Grey
74	Misc. Service/Data Processing	Gray
75	Misc. Service/Data Processing	Gray
76	Misc. Service/Data Processing	Gray
78	Misc. Service/Data Processing	Gray
79	Misc. Service/Data Processing	Gray
80	Doctors' Offices	White
81	Legal Services	White

Two-Digit Standard Industrial Code	Industry Group	Collar Color
82	Educational Services	White
83	Social Services	White
84	Museums and Membership Organizations	White
85	Museums and Membership Organizations	White
86	Museums and Membership Organizations	White
87	Engineering, Architecture, Business Consulting	White
88	Engineering, Architecture, Business Consulting	White
89	Engineering, Architecture, Business Consulting	White
90	Public Administration	White
91	Public Administration	White
92	Public Administration	White
93	Public Administration	White
94	Public Administration	White
95	Public Administration	White
96	Public Administration	White
97	Public Administration	White
99	Unknown/Invalid	Unknown
Unknown	Unknown/Invalid	Unknown

Appendix C: Survey Methodology and Documentation

C.1 DOCUMENTATION

Participating companies provided both claims and exposure data on a monthly basis. The initial data request can be found in Appendix A. For claims information, the following fields were requested:

- Incurred Month
- Reported Month
- Product Type
- Cause of Death
- Number of Claims
- Total Claim Amount Covered/Paid

For exposure information, the following fields were requested:

- Exposure Month
- Product Type
- Exposed Premium
- Number of Inforce Lives

In addition to the above “core” request, participants were also optionally asked to provide the above information split by state, age/sex grouping and industry (two-digit SIC code). The lone exception is that Reported Month was not requested for the claims portion of these three more granular cuts of the data.

Below is a summary of the key processing assumptions and decisions for each of these fields.

Claims–Incurred Month

Incurred Months were generally used as provided without adjustment. The primary exception was that data with an Incurred Month after the as-of-date were excluded. For example, for the December 2022 data submissions, claims with an Incurred Month of January 2023 were excluded.

Claims–Reported Month

Claims with a Reported Month before the Incurred Month were adjusted by setting the Reported Month equal to the Incurred Month.

Claims–Product Type

Carriers were asked to provide data with one of three Product Types: Employee Basic, Employee Supplemental/Voluntary and Retiree Life. All alternative codes received for the Product Type field were sent as data questions to carriers and ultimately mapped to one of these three principal product types. Notably, dependent claims were mapped to one of the two employee types, depending on the code received.

Claims—Cause of Death

Contributors were asked to identify claims as due to one of the 15 cause of death groupings shown in Appendix E.

Claims—Number of Claims and Total Claim Amount Covered/Paid

Claims by Reported Date were processed as is without adjustment. However, on an incurred basis, the claims needed to be adjusted with completion factors as described in Section C.2.1; otherwise, the incidence rates in recent periods would be understated.

Exposure—Exposure Month and Product Type

Processing for these fields was analogous to the corresponding claims fields.

Exposure—Exposed Premium

The proximity of the survey request to the reporting dates of the data requested presented some challenges in the monthly collection process because recent exposure data may be unavailable. For example, one carrier indicated that their premium information for December 2022 was incomplete; therefore, the average premiums for July through September 2022 were imputed for December 2022 for this carrier.

Exposure—Number of Inforce Lives

Not all carriers provided the Number of Inforce Lives. For these carriers, this field was imputed using the average premium per life (PPL) from carriers that supplied both premiums and lives. A separate PPL was calculated for each year and product type, and the missing Number of Inforce Lives was populated by dividing the provided premium by the PPL appropriate to the year and product type for which the premium was earned. The Committee acknowledges that PPL varies by company and that the exposure completion methodology may result in an aggregate incidence rate that differs materially from the actual level of incidence, but the Committee does not expect that it distorted the trends monitored in this study.

Segment Information—State Code

State codes that did not match a listing of valid U.S. state, U.S. overseas territory or Canadian province codes were sent as data questions to the contributors. Some records with indeterminate codes after this questioning process were mapped to an “unknown” category.

Segment Information—Age and Sex

Companies provided age information according to the following categories: 0–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84 and 85+. These age groupings were then lumped into the following broader groupings: 0–44, 45–64 and 65+. Sex information was collected as male, female and unknown.

Segment Information—Industry

For the Industry field, contributors were asked to provide two-digit SIC codes. Codes that did not match a list of valid two-digit SIC codes were sent as data questions to the contributor for resolution. Some records with indeterminate codes after this questioning process were mapped to an “Unknown” category.

C.2 RESULTS PROCESSING AND REVIEW

C.2.1 COMPLETION OF CLAIMS

A table of claim counts by Incurred Month and Reported Month was compiled to develop completion factors. Month-to-month completion factors were estimated using the accumulated totals for a particular incurred month in consecutive reported months. Some seasonal variation was observed in the completion factors, so adjustments to the factors for calendar month were incorporated.

The total completion factors were computed by cumulatively applying the month-to-month completion factors to all subsequent months. For example, the total completion factor for a claim in month 0 is the factor for month 0 to 1, times the factor for month 1 to 2, times the factor for month 2 to 3, and so forth. In total, 36 months of completion were used.

Completion factors vary by calendar month, reflecting the seasonal nature of claim reporting and claim processing speeds. The Committee also incorporated factor variation by reporting speed groups. The rate at which the contributing companies’ claims were completed was analyzed and categorized into five groups, with three to five companies in each reporting speed group.

C.2.2 BROADER CLASSIFICATION OF SEGMENT INFORMATION

For credibility and confidentiality reasons, the industry codes and state codes were grouped into broader segments for analysis. State codes were mapped to one of 11 divisions, with the New England division split into northern and southern portions. The state codes were also mapped to four broader U.S. regions (Northeast, Midwest, Southeast, West), with Canada, overseas territories and unknown codes grouped into a fifth “Other” region.

The two-digit SIC codes were organized into 23 different groupings, and then more broadly into one of four codes by collar color (White, Gray, Blue, Unknown).

A table showing the details of these mappings can be found in Appendix B.

C.2.3 UNKNOWN CLAIM DIAGNOSIS

The Unknown claim diagnosis category is artificially large for September 2022 through December 2022. This is primarily because of the newness of these claims and a reflection of the claim adjudication lifecycle. It is not uncommon to find an additional time lag between the claim reporting date and the point in the claim adjudication process when the COD is known, allowing for the claim to be categorized. As claims data have been collected and refreshed each month, the Committee has observed that the concentration of claims with an unknown COD decreases as the number of months between the original reporting date and the data collection date increases.

C.2.4 COVID-19 CLAIMS FROM 2019 OR EARLIER

The data show a handful of COVID-19 claims with dates of death in 2019 or earlier. The Committee believes that these are coding errors where incorrect COD codes were supplied. These claims remain in the data as submitted without adjustment.

C.2.5 GROUPINGS BY COMPANY SIZE

To review results by company size (see Section 5.4), contributors were split into three groups based on annualized premium amounts from 2019. The Small group consists of companies with less than \$300 million in 2019 premiums, the Medium group consists of companies with between \$300 million and \$1 billion, and the Large group consists of companies with more than \$1 billion. The breakpoints were chosen to ensure at least six companies in each group. The Small group contains six companies, and the Medium and Large groups contain seven companies each.

Appendix D: Completion Factor Development

D.1 BY CLAIM COUNT

Historic Group Life claim reporting patterns by claim count have been studied to develop completion factors. Claims were batched into a claim triangle with incurred month on the horizontal axis and reported month on the vertical axis. Lag is defined as the number of months between when a death occurs and when the claim is reported to a carrier. Thus, a death that was both incurred and reported in August 2020 would have a lag of zero, whereas a death incurred in June 2020, but reported in August 2020, would have a lag of two, and so on.

The completion factors for previous iterations of this report were based on the total set of claims by all causes from all 20 participating carriers, with incurred dates of January 2017 or later and reported dates up through September 2020. Since that time, completion factors have been reviewed periodically. Faster reporting patterns during 2023 made it clear that an update to the completion factors was needed. The revised completion factors used in the development of this report included data for claims reported up through April 2023. The new completion factors had material impacts on estimated incurred claim results for the most recent two months, but only minor impacts for older periods.

Month-to-month completion factors were developed using the accumulated totals for a particular incurred month in consecutive reported months. Seasonal variations were observed during the first two months of lag, so adjustments to the factors for calendar month were incorporated. The total completion factors, as displayed in Table D.1, were computed by cumulatively applying the month-to-month completion factors to all subsequent months.

Table D.1

ESTIMATED COMPLETION FACTORS BY NUMBER OF MONTHS OF LAG AND CALENDAR MONTH

Lag	Jan.	Feb.	Mar.	Apr.	May	June	July	Aug.	Sep.	Oct.	Nov.	Dec.
0	3.1501	3.3325	3.0448	3.0448	3.0448	3.0448	2.9547	2.7549	2.9547	2.8660	3.1501	3.5533
1	1.4586	1.4099	1.4099	1.4099	1.4099	1.4099	1.3682	1.4099	1.3682	1.4099	1.4586	1.4099
2	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752	1.1752
3	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015	1.1015
4	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697	1.0697
5	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530	1.0530
6	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430	1.0430
7	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363	1.0363
8	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314	1.0314
9	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277	1.0277
10	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248	1.0248
11	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221	1.0221
12	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197	1.0197
13	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177	1.0177
14	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162	1.0162
15	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148	1.0148
16	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136	1.0136
17	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126	1.0126
18	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116	1.0116
19	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107	1.0107
20	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098	1.0098
21	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090	1.0090
22	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083	1.0083
23	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076	1.0076
24	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069	1.0069
25	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062	1.0062
26	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056	1.0056
27	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051	1.0051
28	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046	1.0046
29	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042	1.0042
30	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038	1.0038
31	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033	1.0033
32	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030	1.0030
33	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025	1.0025
34	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022	1.0022
35	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006	1.0006

D.2 BY FACE AMOUNT

Our analysis showed that larger face amount claims report faster than lower face amount claims. Thus, over time, the average face amount for an incurral month decreased as claims continued to be reported in later months. For example, the average face amount of claims reported in the first month of an incurral period might be \$40,000 but, three years later, might be \$36,000. This would imply that an adjustment factor of 90% is needed to more accurately complete the total claim amounts.

The development of average claim amounts over time was studied from 2017 to 2019 for each month, and a set of factors was developed to adjust the projected claim amounts in future reports. Table D.2 shows a summarized version of the resulting adjustment factors. These adjustment factors have since been incorporated into the completion factors used within this report.

Table D.2

AVERAGE CLAIM AMOUNT ADJUSTMENT FACTORS BY REPORTING LAG MONTH (ILLUSTRATIVE)

Reporting Lag Month	Adjustment to Average Size
0	86.0%
1	92.7%
2	95.8%
3	97.2%
10	99.1%
20	99.7%
35	100.0%

D.3 BY CAUSE OF DEATH

It was unknown early in the pandemic whether COVID-19 claims would be reported more quickly or slowly than other claims. Assignment of the COD is typically later in the claim adjudication cycle than reporting of the claim, so COVID claims, in general, were expected to complete a bit more slowly than average claims because of the need to complete that step in the adjudication cycle. For deaths in June 2020 through February 2021, it appears that COVID-19 claims were being reported at roughly the same rate as the non-COVID-19 set of claims (see Table D.3). The Committee has reviewed the relative reporting speed of COVID-19 claims at multiple intervals during the pandemic and has concluded that it is not materially different than average; for this reason, the analysis has not been revisited for this report.

Table D.3

CHAIN-LINK FACTORS FOR DEATHS IN JUNE 2020–FEBRUARY 2021

Lag Months	COVID	All Other Causes	COVID/All Other Causes
0	2.188	2.202	99.3%
1	1.203	1.198	100.4%
2	1.062	1.068	99.4%
3	1.031	1.034	99.7%
0-3	2.888	2.916	99.1%

D.4 BY COMPANY REPORTING SPEED

The Committee observed that incurred claim completion rates varied significantly from company to company. Upon analyzing the differences, the 20 contributing companies were grouped into five “reporting speed” groups based on similar reporting patterns. In tandem with the update to total completion factors described in Appendix D.1, the Committee reviewed lag factors by company, resulting in the recategorization of a few companies relative to prior iterations of this report.

The completion patterns for the five groups were compared to the aggregate completion factors and expressed as adjustments in Table D.4. The Committee observed that the differential in completion time was material for the first six reporting months for each incurred period. Further, the Committee did not discern any credible difference in the speed by incurral calendar month; hence, only one vector of adjustments is provided for each group. These adjustments provide a more representative picture for the individual company reports and, to a lesser extent, improve the predictive fit of completed claims in total.

Table D.4
COMPLETION ADJUSTMENT FACTORS BY REPORTING SPEED GROUP

Lag	Group 1	Group 2	Group 3	Group 4	Group 5	Aggregate
0	81.6%	91.9%	106.0%	140.8%	217.8%	100.0%
1	96.3%	97.4%	97.8%	102.0%	112.0%	100.0%
2	100.0%	101.9%	97.5%	96.8%	98.5%	100.0%
3	95.9%	103.5%	95.2%	98.2%	96.3%	100.0%
4	101.1%	98.5%	108.5%	101.4%	101.8%	100.0%
5	108.0%	97.1%	102.7%	109.9%	102.2%	100.0%

Appendix E: Cause of Death Mapping

Table E.1
CAUSE OF DEATH MAPPING

COD Group No.	Group Name	ICD10 Codes	ICD-9 Codes
1	Cancer	C00–C97	140–239
2	Diabetes	E10–E14	249–250
3	Influenza and Pneumonia	J09–J18	480–488 (pneumonia and influenza) or 487–488 (just influenza)
4	Major Cardiovascular Diseases	I00–I09, I11, I13, I20–I51	393–429
5	COVID-19	U07.1, U07.2, B97.29, B97.26, Z03.818, Z20.828, Underlying Cause of Death	Not applicable
6	Accidents (Motor Vehicle)	V02–V04, V09.0, V09.2, V12–V14, V19.0–V19.2, V19.4–V19.6, V20–V79, V80.3–V80.5, V81.0–V81.1, V82.0–V82.1, V83–V86, V87.0–V87.8, V88.0–V88.8, V89.0, V89.2	E810–E829
7	Accidents (Non-Motor Vehicle)	W00–X59, Y86, V01, V05–V06, V09.1, V09.3–V09.9, V10–V11, V15–V18, V19.3, V19.8–V19.9, V80.0–V80.2, V80.6–V80.9, V81.2–V81.9, V82.2–V82.9, V87.9, V88.9, V89.1, V89.3, V89.9, V90–V99, Y85	Subset of 800–959 and 978–999, along with supplemental E-codes
8	Suicide	U03, X60–X84, Y87.0	E950–E959
9	Homicide	U01–U02, X85–Y09, Y87.1	E960–E969
10	Liver	K70, K73–K74	570–573
11	Drug Overdose	This is a subset of accident, assault, suicide and undetermined and requires more than the primary COD to identify: X40–44, X60–64, X85 or Y10–Y14 in combination with any of the following multiple COD codes: T40.9, T40.1, T40.2, T40.3, T40.4 or T40.6	960–977 and E930–E949
12	All Other/Unknown	All claims not in groups 1–11 or 13–15	All claims/codes not in groups 1–11 or 13–15
13	Respiratory	J00–J08, J19–J98	460–479 and 489–519
14	Cerebrovascular, Including Stroke	I60–I69	430–438 and V12.54
15	Alzheimer’s	G30	331

About The Society of Actuaries Research Institute

Serving as the research arm of the Society of Actuaries (SOA), the SOA Research Institute provides objective, data-driven research bringing together tried and true practices and future-focused approaches to address societal challenges and your business needs. The Institute provides trusted knowledge, extensive experience and new technologies to help effectively identify, predict and manage risks.

Representing the thousands of actuaries who help conduct critical research, the SOA Research Institute provides clarity and solutions on risks and societal challenges. The Institute connects actuaries, academics, employers, the insurance industry, regulators, research partners, foundations and research institutions, sponsors and non-governmental organizations, building an effective network which provides support, knowledge and expertise regarding the management of risk to benefit the industry and the public.

Managed by experienced actuaries and research experts from a broad range of industries, the SOA Research Institute creates, funds, develops and distributes research to elevate actuaries as leaders in measuring and managing risk. These efforts include studies, essay collections, webcasts, research papers, survey reports, and original research on topics impacting society.

Harnessing its peer-reviewed research, leading-edge technologies, new data tools and innovative practices, the Institute seeks to understand the underlying causes of risk and the possible outcomes. The Institute develops objective research spanning a variety of topics with its [strategic research programs](#): aging and retirement; actuarial innovation and technology; mortality and longevity; diversity, equity and inclusion; health care cost trends; and catastrophe and climate risk. The Institute has a large volume of [topical research available](#), including an expanding collection of international and market-specific research, experience studies, models and timely research.

Society of Actuaries Research Institute
475 N. Martingale Road, Suite 600
Schaumburg, Illinois 60173
www.SOA.org



Give us your feedback!

Take a short survey on this report.

[Click Here](#)

SOA
Research
INSTITUTE